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 The domestic dog, Canis familiaris, has a unique population structure that lends 
itself to the study of hereditary diseases. Purebred dogs populations are genetically 
isolated and as a result are affected by more than 400 naturally occurring diseases, many 
of which have human counterparts. In the last 15 years, dogs have emerged as a model 
for the study of human hereditary diseases, fueling the development of resources 
including a 7.6X coverage reference genome and single nucleotide polymorphism (SNP) 
genotyping arrays. 
 Congenital myasthenic syndrome (CMS) is a neuromuscular disorder of both 
humans and dogs in which transmission across the neuromuscular junction is 
compromised. Affected individuals exhibit generalized muscle weakness that is 
exacerbated with exercise. To date, 18 genes are known to harbor mutations causative for 
CMS in humans. We characterized a novel CMS in a family of Labrador Retrievers. 
Using whole genome SNP profiles we identified COLQ as a candidate gene. In the 
neuromuscular junction, ColQ acts as an anchor for acetylcholinesterase, which is 
responsible for terminating the signal for muscle contraction. Sequencing revealed a 
missense mutation in exon 14 that predicts the substitution of a threonine for an 
isoleucine at a conserved position.  
The Jack Russell Terrier (JRT) is the first dog breed in which CMS was reported 
in the 1970s. Immunohistochemistry revealed an acetylcholine receptor (AChR) 
deficiency in affected dogs. Analysis of microsatellites flanking the five AChR subunit 
genes indicated that haplotypes encompassing CHRNB1 and CHRNE are consistent with 
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inheritance identical by descent. Sequencing revealed a frameshift mutation in exon 7 of 
CHRNE (G193RfsX272) that is homozygous in recent CMS cases, as well as those from 
the 1970s.  
 Congenital idiopathic megaesophagus (ME) is another neuromuscular condition 
observed in both humans and dogs characterized by an enlarged esophagus. Affected 
dogs are unable to move food into their stomachs, resulting in regurgitation and frequent 
aspiration pneumonia. ME is prevalent among German Shepherd Dogs (GSDs). We 
employed a genome-wide association study to identify genomic regions harboring genes 
underlying ME.  Using 19 affected and 177 unaffected GSDs, we identified an associated 






 I would like to thank my family – my parents Anita and Dave, my sisters Alex 
and Cyndee, my brothers Josh and Nate – for their love and support during my time as a 
PhD student and throughout my life. Thank you to everyone in my lab – Dr. Leigh Anne 
Clark, Dr. Kate Tsai, Dr. Alison Starr-Moss, Dr. Rooksie Noorai – for their instruction, 
help, and guidance. To Jacquelyn Evans, who joined us as a graduate student, and the 
various other undergraduate students that worked in our lab, thank you for teaching me 
patience and reminding me how exciting genetics can be to work with and learn. To my 
other committee members, Dr. Amy Lawton-Rauh, Dr. Meredith Morris, and Dr. Chris 
Saski, thank you for your help and your suggestions from other points of view and 
helping me to see things outside of the scope of my lab. To the dog owners, breeders, and 
veterinarians, thank you for your enthusiasm for and participation in our studies. Finally, 
to Lily, Joy, Rylie, Beau, and all the other dogs in my life, thank you for reminding me 








TITLE PAGE .................................................................................................................... i 
 
ABSTRACT ..................................................................................................................... ii 
 
ACKNOWLEDGMENTS .............................................................................................. iv 
 
LIST OF TABLES ........................................................................................................... v 
 




1. INTRODUCTION ........................................................................................... 1 
 
Dog as a Model System ........................................................................... 1 
Identification of Pathogenic Mutations .................................................... 4 
Congenital Myasthenic Syndromes ......................................................... 9 
Congenital Idiopathic Megaesophagus .................................................. 16 
The Bigger Picture ................................................................................. 17 
References .............................................................................................. 20 
 
2. A COLQ MISSENSE MUTATION IN LABRADOR  
    RETRIEVERS HAVING CONGENITAL  
    MYASTHENIC SYNDROME ...................................................................... 27 
 
Abstract .................................................................................................. 28 
Introduction ............................................................................................ 29 
Materials and Methods ........................................................................... 31 
Results .................................................................................................... 37 
Discussion .............................................................................................. 45 
Acknowledgements ................................................................................ 48 
References .............................................................................................. 48 
     
3. A CHRNE FRAMESHIFT MUTATION CAUSES  
    CONGENITAL MYASTHENIC SYNDROME  
    IN JACK RUSSELL TERRIERS .................................................................. 51 
 
Abstract .................................................................................................. 51 
Introduction ............................................................................................ 52 
Materials and Methods ........................................................................... 54 
vi 
 
Table of Contents (Continued)                                                                                   Page 
 
Results .................................................................................................... 59 
Discussion .............................................................................................. 64 
Acknowledgements ................................................................................ 68 
References .............................................................................................. 68 
   
4. GENOME-WIDE ASSOCIATION STUDIES FOR  
    MULTIPLE DISEASES OF THE GERMAN  
    SHEPHERD DOG ......................................................................................... 71 
 
Abstract .................................................................................................. 75 
Introduction ............................................................................................ 75 
Materials and Methods ........................................................................... 79 
Results .................................................................................................... 82 
Discussion .............................................................................................. 88 
Acknowledgements ................................................................................ 93 
References .............................................................................................. 93 
 
5. CONCLUSIONS, FUTURE DIRECTIONS, AND  
    APPLICATIONS ........................................................................................... 99 
 
A COLQ Missense Mutation in Labrador Retrievers  
Having Congenital Myasthenic Syndrome ................................ 99 
A CHRNE frameshift mutation causes congenital  
myasthenic syndrome in Jack Russell Terriers ........................ 101 
Genome-wide association studies for multiple diseases  
of the German Shepherd Dog .................................................. 102 
Final Thoughts ..................................................................................... 103 
References ............................................................................................ 105 
 
APPENDICES ............................................................................................................. 106 
 
Appendix One (Chapter Two Supplementary Figures) ................................... 107 
Appendix Two (Chapter Four Supplementary Figures) .................................. 112 
Appendix Three (Addendum to Chapter Four) ................................................ 119 
v 
 
LIST OF TABLES 
 
Table                                                                                                                              Page 
 
1.1 Genes involved in human CMS cases and their positions in the NMJ .................... 10 
 
3.1 Microsatellite markers flanking candidate genes ..................................................... 57 
 
3.2 Primers (5'-3') for amplification of CHRNB1 and CHRNE ..................................... 58 
 
3.3 Jack Russell Terriers genotyped for G193RfsX272 ................................................ 64 
 
4.1 Frequency data for SNP 12.60274687 in GSDs with and without ME ................... 86 
vi 
 
LIST OF FIGURES 
 
 
Figure                                                                                                                            Page 
 
1.1 Linkage disequilibrium (LD) in and between breeds ................................................ 2 
 
1.2 Proteins of the neuromuscular junction ................................................................... 11 
 
2.1 Multigenerational pedigree of Labrador Retrievers ................................................. 36 
 
2.2 Peroneal MNCV of an affected Labrador Retriever recorded at the  
extensor digitorum brevis muscle with stimulation at the level of  
the hock, stifle, and hip ...................................................................................... 39   
 
2.3 Repetitive stimulation of the peroneal motor nerve of an affected  
Labrador Retriever at 2Hz (A), 5Hz (B), and 50Hz (C) .................................... 39   
 
2.4 Cryosections (8µm) of intercostal muscle from a normal dog, a  
Labrador Retriever with CMS (end-plate AChE deficiency),  
and a Jack Russell Terrier with CMS due to AChR deficiency  
(neuromuscular disease control) are illustrated ................................................. 41 
 
2.5 Microsatellite and SNP haplotypes (color-coded bars below  
individuals) are shown for 3 candidate genes .................................................... 43 
 
2.6 (A) Sequence from the 5’ end of the C-terminal domain of  
ColQ in mammals.  
      (B) BtsI digest results for the Labrador Retriever family ........................................ 44 
 
3.1 Microsatellite haplotypes flanking the AChR subunit genes ................................... 62 
 
3.2 Direct sequences from unaffected, carrier, and affected Jack  
Russell Terriers .................................................................................................. 63 
 
3.3 Amino acid alignment of wild-type dog CHRNE and sequence  
with G193RfsX272 mutation ............................................................................. 65 
 
4.1 Principal component analysis of the GSD cohort shows all 197  
dogs clustering together ..................................................................................... 83 
 
4.2 Manhattan plots showing the results for GWAS using 48,415  










Dog as a Model System 
 Diseases and disorders have plagued mankind from the beginning of the species, 
and the attempts to study these diseases have led to both great discoveries and great 
moral outrage. As scientists began to recognize commonalities with the creatures around 
us, they began to use model organisms for the study of human diseases to continue the 
discoveries while staying within ethical boundaries. These animals, including the most 
well-known models Drosophila melanogaster (fruit fly), Mus musculus (mouse), and 
Rattus spp. (rat), were used in place of humans due to ethical concerns about 
experimenting on humans and, later, because their genomes are similar to that of humans. 
In addition, numerous other model organisms have contributed to our knowledge of 
genes and heredity. Among these is Canis familiaris, the domestic dog. Like other model 
organisms, dogs produce more offspring than humans, can be selectively bred, and have 
shorter lifespans, features which allow for the assembly of large pedigrees and the study 
of disease progression. Other characteristics of dogs enable opportunities for study that 
are not available in traditional model systems.  
First, the dog population as a whole is divided into specific breeds, each of which 
is a genetically isolated population as a result of artificial selection [1]. This artificial 
selection took the form of two bottlenecks in the domestic dog’s history: the original 
domestication from the gray wolf and the derivation of specific breeds possessing 
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desirable traits such as behavior/personality, speed, aggression, coat color, height, and 
others [2]. In order to maintain breed standards, a concept known as the “breed barrier” 
was instituted; that is, dogs are considered “purebred” only if both of their parents are 
registered as members of the same breed, and there is no crossbreeding between the 
different breeds. Therefore, no new genetic variation is introduced into registered dog 
breeds. This genetic isolation leads to linkage disequilibrium (LD) – the inheritance of 
alleles at adjacent loci more often together than would be observed by chance – that is 
longer within the same breed (several megabases; [2]) and shorter between different 
breeds (tens of kilobases; [2]) (Figure 1). In genomic mapping studies, the longer LD 
within a breed is often used to initially identify a region of interest associated with the 
trait under study [2]. Shorter LD between breeds is then used to narrow these regions by 




Figure 1. Linkage disequilibrium (LD) in and between breeds. Studies using LD assume 
a founder mutation (blue crescent) in a common ancestor of multiple breeds. As the 
breeds diverge from one another through selection for different traits, different 
recombination events will occur around the location of the founder mutation in each 
breed. Therefore, while the length of the shared LD within a breed will be longer, the 
length of the shared LD between breeds will be relatively shorter as can be observed at 
the bottom of the figure.  
  
Because dogs are kept as pets, they are exposed to many of the same 
environmental factors as humans, allowing for environmental comparisons to be made 
between dogs and humans [1]. The majority of pet owners keeps dogs in their houses, 
take them along on trips in the car or to parks, and otherwise share their daily lives and 
concurrent environmental influences with their pets. Additionally, most pets receive 
medical care comparable to that of humans as the majority of owners take their dogs to a 
veterinarian on a regular basis [1]. Veterinary care involves medical history records as 
well as treatment, which contributes information on disease etiology and progression that 
can be used in studies [1].  
Moreover, there is a very large pet population in the United States, with about 70 
million dogs as pets as of 2012 [3]. Thus, there is rarely a need for establishing the 
colonies necessary for the study of mice, rats, and other such model organisms. Blood or 
buccal cells can be collected from affected and unaffected dogs from this general pet 
population for this isolation of genomic DNA.  
Lastly, and perhaps most importantly, there are about 220 naturally-occurring 
diseases in dogs that have an analogous disease in humans, and this list is continually 
growing [4]. The occurrence of spontaneous diseases in dogs provides a model system 
that more closely follows the progression as well as the etiology of a given disease than 
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an experimentally induced version of the same disease [1]. There are even documented 
cases of the same genotype causing the same phenotype in both dogs and humans, such 
as the C2T mutation causing retinitis pigmentosa in humans and progressive rod-cone 
degeneration in dogs [5], further supporting the dog as a system that closely parallels 
humans. 
 
Identification of Pathogenic Mutations  
 In the dog, as in other animals, there are three types of mutations that can result in 
new phenotypes: de novo somatic mutations, de novo germline mutations, and founder 
mutations. In the case of a de novo somatic mutation, the affected dog is the first to 
harbor the causative mutation as it is a result of a change in that individual’s somatic cell 
DNA. As this type of mutation does not occur in germline cells, it is not passed on to 
offspring, and only the dog in which the mutation originated is affected. In the case of a 
de novo germline mutation, the mutation originates in a parent’s germline cells and then 
is passed on to the offspring. While, the parent is not affected, one offspring does exhibit 
the new phenotype. The new mutation may now be present in the germline cells of the 
affected offspring, it will be passed on to their offspring and so on down the generations. 
This type of mutation will potentially appear multiple times on a pedigree after the dog in 
which the original mutation event occurred.  
 Founder mutations originate in an ancestor that was among the founders of a 
population, in this case the dog breeds discussed here, and are present in both the somatic 
cells (resulting in affected or carrier dogs) and the germline cells (resulting in affected or 
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carrier offspring). In dog breeds, founder mutations result in multiple carriers and 
affected dogs within a breed as the original mutation occurred in a common ancestor. 
Such mutations are present in several generations in pedigrees and can sometimes be 
traced back to the original ancestor. This type of mutation makes genetic studies using 
LD within and between dog breeds possible. In cases of founder mutations from a more 
distant common ancestor of several breeds, the mutation may be present in multiple dog 
breeds (i.e., the SILV insertion causative for merle coat color in Shetland Sheepdogs, 
Collies, and several other breeds [6]). Other founder mutations that originate in dogs that 
were founders of a specific breed will be observed within that breed but not in other 
breeds (i.e., the CHAT mutation in Old Danish Pointing Dogs [7] and the COLQ mutation 
in Labrador Retrievers that both result in congenital myasthenic syndromes [8]). These 
differences must be taken into account when conducting genetic studies in dogs.  
 One practical approach to studies of genetic diseases in dogs is the candidate gene 
approach, in which genes known to harbor causative mutations in other species for the 
same trait or disease are evaluated for mutations in the species under study. For dog 
studies, these candidate genes are usually found in cases of the same disease in humans. 
For example, Winkler and colleagues identified a mutation involved in oculocutaneous 
albinism in Doberman Pinschers by evaluating four genes known to harbor mutations for 
this condition in humans [9]. By examining markers flanking each of the candidate genes, 
they found that the affected dogs shared the same marker alleles around SLC45A2 [9]. 
Sequencing of this gene revealed a 4,081bp deletion that causes the loss of the end of 
exon 7 [9].  
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 If no potential candidate genes are known, or if too many candidate genes are 
known – making sequencing all of them not financially feasible – mapping approaches 
can be utilized. In the first years of the 21
st
 century, the whole genome of a Boxer was 
sequenced to 7.6x coverage (canFam1 and canFam2 builds) [2]. This whole genome 
reference sequence was used to identify single nucleotide polymorphisms (SNPs), which 
are single bases at specific loci that vary between individuals in over 1% of the 
population scanning the Boxer sequence for supported alternative alleles, 2) comparing 
the Boxer sequence to that of the Standard Poodle (1.5x coverage; [10]), and 3) 
comparing the Boxer sequence to from 9 other dog breeds (0.02x coverage), 1 coyote 
(0.004x coverage), and 4 gray wolves (0.004x coverage) [2]. To facilitate more 
comprehensive data collection, the gaps in the genome were later filled in, resulting in the 
build known as canFam3 [11]. These sequences were used to create SNP arrays which 
allow for the simultaneous genotyping of tens of thousands of markers.  
 The SNP arrays developed from the builds of the canine genome have allowed for 
the use of genome-wide association studies (GWASs) in the dog. GWAS involves the use 
of marker data across the genome, usually SNP data, in identifying regions of association 
with a disease or trait based on case/control analyses. Performing a GWAS with cases 
and controls from one breed can reveal regions of interest within the genome due to the 
long LD that is present within breeds [2]. Because of this LD structure, surprisingly small 
numbers of dogs can be used to identify genomic regions harboring positional candidate 
genes for simple recessive diseases [12,13]. As technology is advanced, these tools for 
studying genetics and heredity in the dog continue to change and improve. 
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 Closer relationships among dogs of one breed create longer LD within that breed, 
resulting in longer chromosomal segments that are inherited together. In mapping studies, 
this longer LD can be exploited to identify regions that have many markers inherited with 
the allele causative for the trait or disease of interest [2]. Therefore, the longer LD within 
breeds allows for simple Mendelian traits to be mapped using small sample sizes. For 
example, the causative mutation for episodic falling syndrome (EFS), an autosomal 
recessive disease of Cavalier King Charles Spaniels, was identified through the use of a 
population of seven unaffected, five affected, and one obligate carrier [13]. These dogs 
were genotyped on an Affymetrix SNP array, a case/control analysis run, and the p-
values for each SNP calculated [13]. Recombination events in an obligate carrier and one 
of the affected dogs defined a 3.48Mb shared haplotype on canine chromosome 7 (CFA 
7). Investigation of positional candidate genes led to the discovery of a causative 
microdeletion in BCAN [13].  
 The short LD between breeds can also be advantageous, particularly in the study 
of complex diseases. For example, canine squamous cell carcinoma of the digit (SCCD) 
is a complex disease that affects several breeds, including Standard Poodles [14]. Thirty-
one affected Standard Poodles and thirty-four unaffected Standard Poodles were used in a 
GWAS covering 36,897 SNPs [14]. Through this analysis, the authors identified an 
association on CFA15 [14]. Thirty-eight cases and thirty controls were then used for 
recombination mapping and another association analysis in order to further narrow this 
region [14]. These analyses revealed KITLG as a candidate gene, which the authors then 
sequenced; however, none of the variants identified segregated with SCCD [14]. 
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Analyses of Standard Poodles compared to Giant Schnauzers and Briards resulted in an 
association with a 144.9kb segment of CFA15, and eventually the authors were able to 
narrow the region even further to a 5.7kb haplotype that included KITLG [14]. They 
investigated the copy numbers of this region between cases and controls and found that 
the affected dogs had more copies of this region compared to the unaffected dogs [14]. 
Therefore, the authors posit that a copy number variation (CNV) at this locus is the cause 
of SCCD [14]. 
 Many genetic diseases involve both a genetic and environmental component. An 
example is dermatomyositis (DM). DM is an inflammatory skin disease with variable 
ages of onset observed primarily in Collies and Shetland Sheepdogs [15-17]. The 
occurrence of this disease in two breeds but not across the dog population indicates a 
strong heritable component; however, anecdotal reports describe the onset of clinical 
signs occurring following vaccinations, abandonment, and other stressors, suggesting an 
environmental trigger. In fact, human cases of DM are associated with alleles of the 
major histocompatibility complex (MHC), but not all individuals with the DM genotype 
will develop the disease [18]. Complex diseases like DM require larger study populations 
to detect genomic region(s) playing a role in pathogenesis (e.g.,[19]).   
 While many studies have made use of the dog’s unique genetic structure, there are 
few studies in which the functions of genes and causative mutations identified in the dog 
are examined. That is, unlike many human studies involving the transfection of mice 
models with the human mutation to determine if that mutation results in a similar 
phenotype to that of the human, there are few studies in the dog that involve such 
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functional studies. There are also far fewer studies in the dog leading to therapies for 
genetic diseases. Therefore, there is room for development of this field in the canine 
genetics world, particularly as it pertains to therapies for dog genetic diseases. In other 
words, through the development of functional genomics studies in the dog, therapies that 
can be used to treat genetic diseases of the dog may be found, and these therapies may 
also be of use for the humans affected with analogous diseases.  
 
Congenital Myasthenic Syndromes 
Congenital myasthenic syndrome (CMS) is a disease that affects both humans and 
dogs. CMSs affect between 25 and 125 per million people and usually presents very early 
in life, with the specific age of onset varying by type [20]. CMSs are disorders of the 
neuromuscular junction (NMJ), the region in which the motor neuron sends the signal for 
muscle contraction to the muscle. There are three regions within the NMJ: the 
presynaptic region, the synapse, and the postsynaptic region. In normal transmission 
across the NMJ (Figure 2), ACh is produced in the motor neuron, a process in which 
choline acetyltransferase (ChAT) is involved [20]. ACh is released from the motor 
neuron and travels across the NMJ to bind to the AChRs, triggering muscle contraction. 
AChE breaks down excess ACh so that the muscle contraction is not prolonged [21], 
while ColQ attaches to and anchors asymmetric AChE to the basal lamina of the muscle 
cell. Other proteins involved in this process, such as agrin [20], rapsyn [20], Nav1.4 [20], 
MuSK [20], and Dok-7 [22], mostly participate in the development of the NMJ, in 
clustering of the AChRs, or in the process of muscle contraction (Figure 2). Other 
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proteins listed in Table 1 are glycosylation genes in which mutations have also been 
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Figure 2. Proteins of the neuromuscular junction. Pathway described above in text.  
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In muscles, the AChR is made up of 5 subunits: alpha (α; encoded by CHRNA1), 
beta (β; encoded by CHRNB1), gamma (γ; encoded by CHRNG), delta (δ; encoded by 
CHRND), and epsilon (ε; encoded by CHRNE). Until the 31
st
 week of development, the 
AChR is comprised of 2 α subunits, 1 β subunit, 1 γ subunit, and 1 δ subunit. At that 
time, the γ subunit is replaced by the ε subunit).  ACh attaches to the AChR at the α/δ and 
the α/ε interfaces [20], triggering the contraction of the muscle cell through the 
conformational change of the AChR penatmer [20].   
 In humans, the most common mutations in CMS occur in genes encoding the 
AChR subunits that comprise the adult AChR, with approximately 50% of the mutations 
in CHRNE and less than 1% each in CHRNA1, CHRNB1, and CHRND [20]. There are 
three types of CMS that are caused by mutations in these genes: slow-channel CMS 
(SCCMS), fast-channel CMS (FCCMS), and AChR deficiency [20,23]. Each of these 
types has different clinical signs and different mutations in these 4 genes associated with 
them [20,23]. 
 While almost all forms of CMS are autosomal recessive, SCCMS is inherited in 
an autosomal dominant manner [24-27]. The onset of SCCMS can occur from childhood 
to adulthood with a range of severity, and the clinical signs include severe weakness of 
the finger extensor, wrist, and neck muscles as well as progressive respiratory problems 
[20]. These clinical signs are the product of the AChR’s extended activation due to ACh 
in the NMJ, which in turn results in extended muscle contraction resulting in repetitive 
compound muscle action potentials (CMAPs) [28]. Eventually, these changes result in 
damage to the junctional folds, which cause a loss of AChRs [20]. 
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 Fast-channel CMS (FCCMS) is inherited as an autosomal recessive trait [24-
25,29] and in many ways is the opposite of SCCMS. The mutations causing FCCMS can 
affect one or multiple functions of the AChR, including the AChR’s gating efficiency, its 
channel kinetics stabilization, and/or its ACh affinity [20]. Unlike in SCCMS, the 
structure of the postsynaptic membranes in FCCMS is conserved [20]. The severity of the 
clinical signs ranges from mild to severe [20] and can include bulbar muscle weakness 
and apneic, or respiratory, crisis [23]. 
 AChR deficiency is inherited in an autosomal recessive manner, and the 
associated mutations are homozygous or compound heterozygous [20]. The majority of 
these mutations are located in CHRNE [20]. The onset of clinical signs is early, and they 
range from mild to severe, including weakness of the limb and bulbar muscles as well as 
ptosis and external ophthalmoplegia [20]. This type of CMS is marked by a reduction of 
AChR in the postsynaptic region [20], but the junctional folds are not damaged [20]. In 
some cases, a milder phenotype is observed due to the presence of the γ subunit, the fetal 
subunit which the ε subunit replaces during development [20]. 
Another common form of CMS, referred to as end-plate AChE deficiency (EAD), 
is an autosomal recessive disorder caused by mutations in COLQ and represents 
approximately 10-15% of CMS cases [20]. Due to the lack of AChE in the NMJ, 
cholinesterase inhibitors either do not affect or can worsen the clinical signs of EAD [20]. 
COLQ encodes the collagen-like tail subunit of asymmetric acetylcholinesterase, and 
three of these subunits form a homotrimer that attached to asymmetric AChE. ColQ 
anchors this complex to the basal lamina of the muscle cell and in this position, and 
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AChE breaks down excess ACh so that the muscle contraction is not continuous [21]. In 
EAD CMS cases, the absence of ColQ (and therefore AChE) at the NMJ results in the 
accumulation of ACh, which leads to continuous muscle contraction and, ultimately, 
AChR desensitization [30].  
 Another approximately 15-20% of CMS cases involve missense and frameshift 
mutations in RAPSN [31] [32] [33] and are referred to as rapsyn deficiency [23]. These 
mutations are also inherited in an autosomal recessive manner [20]. There are two types 
of rapsyn deficiency – early and late onset [20]. In early-onset rapsyn deficiency, the 
clinical signs range from mild to severe and include neonatal respiratory failure, 
hypotonia, episodic apnea, and arthrogryposis multiplex congenital [20]. Late-onset 
rapsyn deficiency includes clinical signs such as weakness of the limbs and facial 
muscles [20,34]. At the NMJ, rapsyn is involved in consolidating the AChRs at the 
endplate by associating with itself and then aggregating the AChRs, attaching them to the 
cytoskeleton of the muscle cell [20]. In cases of rapsyn-deficiency CMS, however, the 
mutations in RAPSN result in either the inability of rapsyn to associate with itself [35] or 
to cluster with AChR [20].  
 DOK7 mutations account for about 10-15% of CMS cases [36]. This type of CMS 
is known as DOK7-associated limb-girdle-myasthenia, and these mutations are inherited 
in an autosomal recessive manner [20]. The clinical signs include ptosis, waddling gait, 
and weakness of the limbs and torso muscles [20]. DOK7 encodes the protein 
downstream of kinase-7 (docking protein 7, or Dok-7), which plays a role in 
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synaptogenesis [20]. In addition, Dok-7 interacts with another protein of the NMJ known 
as MuSK [22] and acts as an activator of the kinase activity of MuSK [20].  
 The treatment of CMS varies with the location of the causative mutation. For 
example, anticholinesterase medication (cholinesterase inhibitors) are usually used for the 
treatment of many cases of AChR subunit mutation CMS, but they are either ineffective 
or can worsen clinical signs in CMSs caused by COLQ mutations [30,37-38]. Therefore, 
it is important to determine the type of CMS before deciding on the form of treatment. 
 Most CMS studies are conducted in humans as CMSs are rare in veterinary 
medicine. In dogs, CMS usually presents when the puppies are around 6 to 12 weeks old. 
The clinical signs of CMS can vary, but the common clinical signs include generalized 
muscle weakness. Many owners opt to euthanize their dogs if the dogs’ clinical signs 
progress. There are a few treatments available, but the efficacy of these treatments varies 
from case to case, usually corresponding with the gene involved [39]. For example, most 
CMSs involving mutations in AChR subunit genes can be treated with anticholinesterase 
medication, while clinical signs in CMSs involving mutations in COLQ are made worse 
if the same medication is administered [39-40]. To date, cases of CMS have been 
reported in Jack Russell Terriers [41], Springer Spaniels [42], Smooth Fox Terriers [43], 
Old Danish Pointing Dogs [44], and Miniature Dachshunds [45]. While these studies 
describe the clinical aspects of CMS such as the clinical signs, onset, and possible mode 
of inheritance, as of this writing, molecular genetics studies have only identified two 
mutations in veterinary CMSs: a CHRNE missense mutation in Brahman cows [46] and a 
CHAT missense mutation in Old Danish Pointing Dogs [7]. 
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Congenital Idiopathic Megaesophagus 
 Megaesophagus (ME) is another disease that affects both humans and dogs. This 
disease is characterized by the dilation of the esophagus [47]. In humans, ME most often 
occurs secondary to esophageal achalasia [48]. In dogs, ME can be either acquired or 
inherited [47]. Because the muscles of the esophagus are affected, this disorder results in 
the inability to swallow food and affected individuals are malnourished.  
 In dogs, both secondary acquired and congenital idiopathic forms of ME have 
been observed [47]. Secondary acquired ME is usually associated with another disorder 
such as myasthenia gravis or congenital myasthenic syndrome [43,49-50]. The congenital 
form of megaesophagus, known as congenital idiopathic ME usually presents before 
maturity, most often shortly after the puppies are weaned [47]. The clinical sign after 
which the disease is named is an enlarged esophagus, which can be visualized by 
radiographs and/or barium swallow [47].  
 Another clinical sign is regurgitation, which should be differentiated from 
vomiting for an accurate diagnosis [47]. Regurgitation occurs when food or water is 
expelled from the mouth or esophagus that has not been in the stomach [47]. Vomiting, 
on the other hand, occurs when material is forcibly expelled from the stomach [47]. In 
dogs affected with megaesophagus, the food that they ingest is mostly either regurgitated 
or trapped in the enlarged esophagus [47]. Because of this, affected dogs suffer from 
malnourishment, and the food trapped in the esophagus can be inhaled, resulting in 
aspiration pneumonia, which can be fatal [47].  
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 While there is no cure for congenital ME, there are treatments available, including 
the use of a Bailey chair,  a device that elevates the dog’s food dish and head so that 
gravity can move the food to the stomach [47]. In addition, high-calorie food can be used 
to increase the amount of nutrients the dog consumes at each meal [47]. This disease is 
prevalent in several dog breeds, including Dachshund, German Shepherd Dogs, 
Miniature Schnauzers, Wire Fox Terriers, Great Danes, and Rhodesian Ridgebacks, but it 
has also been observed in other breeds [51]. Congenital ME is hereditary and appears to 
have different modes of inheritance in different breeds (e.g., [51-60]. In German 
Shepherd Dogs, one of the breeds affected by congenital ME, the mode of inheritance 
appears to be more complex than a simple recessive or dominant trait [61].  
 
The Bigger Picture 
 The following chapters describe my investigations into the genetic underpinnings 
of CMS in the Labrador Retriever [8], CMS in the Jack Russell Terrier, and congenital 
ME in the German Shepherd Dog [61]. In chapter two, a novel CMS was identified in a 
family of Labrador Retrievers in which a missense mutation in COLQ is associated with 
the CMS phenotype [8]. Candidate genes were identified using a novel approach in dogs 
in which the SNP genotypes obtained through array analysis were evaluated for 
frequencies following the pattern of recessive inheritance (i.e., 1.0 in affected dogs and 
between 0.14 and 0.5 in unaffected parents and littermates) [8]. This method of 
examining the allele frequencies within a family was adapted from a method described in 
a paper by Roach and colleagues [62]. In this work, the authors used a family of 4 (2 
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parents and 2 affected offspring) to identify genomic regions segregating with 2 recessive 
disorders [62]. With this method, 3 functional and positional candidate genes and a 
mutation that segregates with CMS in this Labrador Retriever family were identified [8].  
 In chapter three, another form of CMS was identified in Jack Russell Terriers. In 
our original family, there were 2 affected siblings, 1 unaffected sibling, and both parents 
were healthy. The affected puppies presented with fatigue and muscle weakness. CMS 
has been previously reported in Jack Russell Terriers [41,63-65]. CMS was first 
described in this breed in 1974 [41]. A later study also described clinical signs similar to 
those of the Jack Russell Terriers in our study [63]. Further studies found an AChR 
deficiency in affected Jack Russell Terriers [64]. Wallace and Palmer reported that CMS 
in Jack Russell Terriers appears to be autosomal recessive [65]. We concluded that the 
CMS described in the 1970s and 1980s in Jack Russell Terriers is very similar and most 
likely the same disease that observed in our study family [41,63-64]. Because the affected 
dogs had an AChR deficiency, a candidate gene approach was used and the 5 genes 
encoding receptor proteins were investigated.  A frameshift mutation in CHRNE that 
segregates with the CMS phenotype in modern cases and those from the 70’s and 80’s 
was identified.  
 CMS can be devastating to breeders and dog owners as they usually progress until 
the dog’s quality of life is so poor that the owners opt for euthanizing the animals. In 
chapters two and three, tests for CMS in Labrador Retrievers and Jack Russell Terriers 
were developed [8]. With these tests, breeders can screen their dogs before breeding 
them, thereby lowering the chances of breeding carriers together. If carrier matings are 
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avoided, it is likely that the recessive diseases can be eliminated from the population. 
This is particularly important in dogs because they are closed breeding populations with 
low genetic diversity. Because these screens can detect carriers, breeders then have the 
option to breed a carrier to a non-carrier so that carriers with other desirable traits do not 
have to be completely removed from the breeding pool.   
 In addition, the results of the CMS studies indicate that, at least for the three 
known CMS mutations in dogs [7-8], CMS is inherited as an autosomal recessive 
disorder. Furthermore, different dog breeds exhibit different CMSs, indicating that other 
affected breeds most likely harbor mutations in different genes than those already 
identified (e.g., [7-8]). Veterinarians should also be made aware that, like human CMS 
cases, different types require different treatments.  
 In chapter four, our study of congenital ME in German Shepherd Dogs, utilized a 
GWAS approach [61]. Whole genome SNP profiles from 19 affected and 177 unaffected 
German Shepherd Dogs were used in a case/control study with German Shepherd Dogs 
affected with congenital ME as cases and German Shepherd Dogs that were either 
healthy or diagnosed with other diseases as controls [61]. Through this analysis, a 
segment on CFA12 associated with congenital ME harboring several SNPs was defined 
[61]. Several additional affected German Shepherd Dogs were genotyped for these SNPs 
[61]. While a candidate gene was not identified, SNP 12.60274687 was found to be 
strongly associated with the congenital ME phenotype [61].   
 Congenital ME is most likely the result of a founder mutation in the German 
Shepherd Dog as many members of this breed are affected. However, unlike the simple 
20 
 
recessive mutations observed in the two cases of CMS, congenital ME appears to have a 
more complex inheritance pattern [61]. The fact that the SNP associated with the 
congenital ME phenotype was present among healthy control dogs suggests incomplete 
penetrance, perhaps due to modifier loci [61] or the involvement of an environmental 
component. A second GWAS conducted using other breeds affected with ME could 
allow for the identification of a smaller shared haplotype, while re-sequencing of the 
associated region in an affected dog could yield candidate causal mutations.      
 In conclusion, different approaches have been used in my studies to investigate 
the genetic causes of three different diseases of dogs. While chapters three and four 
utilize standard candidate gene and GWAS approaches, respectively, chapter two 
demonstrates for the first time that whole genome SNP profiles from nuclear family 
members can be used to assess genomic inheritance patterns and identify functional and 
positional candidate genes. In addition, genetic tests have been developed that are now 
available for CMS in the Labrador Retriever and the Jack Russell Terrier. Used properly, 
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Congenital myasthenic syndromes (CMSs) are heterogeneous neuromuscular disorders 
characterized by skeletal muscle weakness caused by disruption of signal transmission 
across the neuromuscular junction (NMJ). CMSs are rarely encountered in veterinary 
medicine, and causative mutations have only been identified in Old Danish Pointing 
Dogs and Brahman cattle to date. Herein, we characterize a novel CMS in 2 Labrador 
Retriever littermates with an early onset of marked generalized muscle weakness. 
Because the sire and dam share 2 recent common ancestors, CMS is likely the result of 
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recessive alleles inherited identical by descent (IBD). Genome-wide SNP profiles 
generated from the Illumina HD array for 9 nuclear family members were used to 
determine genomic inheritance patterns in chromosomal regions encompassing 18 
functional candidate genes. SNP haplotypes spanning 3 genes were consistent with 
autosomal recessive transmission, and microsatellite data showed that only the segment 
encompassing COLQ was inherited IBD. COLQ encodes the collagenous tail of 
acetylcholinesterase, the enzyme responsible for termination of signal transduction in the 
NMJ. Sequences from COLQ revealed a variant in exon 14 (c.1010T>C) that results in 
the substitution of a conserved amino acid (I337T) within the C-terminal domain. Both 
affected puppies were homozygous for this variant, and 16 relatives were heterozygous, 
while 288 unrelated Labrador Retrievers and 112 dogs of other breeds were wild-type. A 
recent study in which 2 human CMS patients were found to be homozygous for an 
identical COLQ mutation (c.1010T>C; I337T) provides further evidence that this 
mutation is pathogenic. This report describes the first COLQ mutation in canine CMS and 
demonstrates the utility of SNP profiles from nuclear family members for the 
identification of private mutations.  
 
Introduction 
Skeletal muscle contraction is stimulated by the emission of the neurotransmitter 
acetylcholine (ACh) by the motor neuron, and terminated by acetylcholinesterase (AChE) 
in the neuromuscular junction (NMJ). Disruption of signal transmission within the NMJ 
resulting from presynaptic, synaptic, or post-synaptic defects causes congenital 
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myasthenic syndromes (CMSs), heterogeneous neuromuscular disorders characterized by 
skeletal muscle weakness and fatigue. Mutations causing CMSs in humans have been 
identified in 18 genes to date, with a majority of cases attributed to CHRNE, COLQ, 
RAPSN, and DOK7 [1]. Mutations are predominantly autosomal recessive, and often act 
in compound heterozygosity [2-5].  
Naturally-occurring CMSs are rarely described in veterinary medicine; when they 
do occur, they are usually in animals between 6 to 12 weeks of age, appear to be familial, 
and are characterized by severe generalized skeletal muscle weakness.  The first report of 
canine CMS was in the Jack Russell Terrier in 1974 [6]. Since that time, acetylcholine 
receptor (AChR) deficiency has been confirmed in Jack Russell Terriers [7], as well as 
Smooth Fox Terriers [8].  CMS has also been clinically described in families of Springer 
Spaniels [9], Miniature Smooth-Haired Dachshunds [10], and Old Danish Pointing Dogs 
[11]. Characterization of CMS at the molecular level has only been achieved in Old 
Danish Pointing Dogs (missense mutation in CHAT) [12], and in young Brahman cows 
(deletion in CHRNE) [13].  
 Diagnosis of CMS is challenging and relies on clinical evaluation, morphological 
studies of muscle and peripheral nerves, electrodiagnostic studies, the absence of serum 
antibodies against muscle AChRs, demonstration of AChR deficiency, and most recently, 
molecular genetic studies. We have identified a novel canine CMS in a family of 
Labrador Retrievers. Affected littermates exhibited signs clinically distinct from 
neuromuscular disorders previously characterized in the breed: exercise-induced collapse 
(EIC) [14], centronuclear myopathy (CNM) [15], and myotubular myopathy [16].  
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While genome-wide association studies (GWAS) are an efficient approach for the 
identification of recessive alleles, they require several unrelated affected individuals [17-
19]. In the absence of a population suitable for GWAS, we utilized genome-wide SNP 
profiles from a nuclear family to evaluate inheritance patterns in chromosomal regions 
harboring all 18 candidate genes. Described herein is the clinical characterization of CMS 
in a Labrador Retriever family and identification of a missense mutation in COLQ.  
 
Materials and Methods 
Animals 
The dogs evaluated in this study were members of a Labrador Retriever family. 
The dam and sire were clinically normal and both tested clear for the EIC [14] and CNM 
[15] mutations affecting the Labrador Retriever breed. At 6 weeks of age, 2 female 
puppies from a litter of 9 were presented to the Texas A&M University (TAMU) 
Veterinary Teaching Hospital with a 3- to 4-week history of exercise-induced 
tetraparesis. One puppy was euthanized for progression of clinical signs at 7 weeks of 
age. Further evaluation including electrophysiology and blood and tissue collection was 
performed prior to euthanasia of the second puppy. No clinical signs of weakness were 
observed in 6 littermates (1 puppy died at birth), and a neuromuscular disease had not 






Sample Collection and DNA Isolation 
 Whole blood was drawn from family members by their primary care 
veterinarians. Buccal swabs were collected from additional Labrador Retrievers, both 
related and unrelated to the affected dogs. DNAs from Labrador Retrievers and other 
breeds previously collected for unrelated studies were also available. Informed owner 
consent and all samples were obtained in accordance with protocols approved by the 
Clemson University Institutional Review Board (IBC2008-17).  Owner consent was 
obtained for post-mortem tissue collection from both affected puppies at TAMU. 
Genomic DNA was isolated using Gentra Puregene Blood Kit (Qiagen).  
 
Electrophysiology 
 Electrodiagnostics on the affected second puppy, including electromyography 
(EMG), measurement of motor nerve conduction velocity (MNCV), and measurement of 
the decrement in the compound muscle action potential (CMAP) following repetitive 
nerve stimulation, were performed on the left side under general inhalational anesthesia 
using a Nicolet Viking Select EMG/evoked potential system (Nicolet, Biomedical Inc.). 
Insulated stainless steel needle electrodes were used for both nerve stimulation and 
recording from muscle, while a platinum subdermal electrode
 
(Grass-Telefactor) was 
employed as a ground.  MNCV of the peroneal and ulnar nerves was determined by 
dividing the distance between proximal and distal stimulation sites by the difference in 
latency of the corresponding CMAP recorded from the extensor digitorum brevis muscle 
and palmar interosseous muscles, respectively, after supramaximal stimulation (2Hz 
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stimulus rate, 0.2ms stimulus duration). Amplitude (peak to peak) was measured from 
CMAPs derived from stimulation at the proximal and distal stimulation sites. Repetitive 
nerve stimulation parameters included stimulation frequencies of 1, 2, 3, 5, 10, 20, or 
50Hz. 
Histopathology, Histochemistry, and Immunohistochemistry 
 Specimens collected post-mortem from the second puppy included the 
infraspinatus, extensor carpi radialis, triceps brachii, biceps femoris, quadriceps, and 
cranial tibial muscles on the right side. The muscles were frozen in isopentane pre-cooled 
in liquid nitrogen and stored at -80ºC until further processing. Light microscopic 
evaluation of histological and histochemical stains and reactions was performed 
according to standard protocols [20] and included hematoxylin and eosin, modified 
Gomori trichrome, periodic acid Schiff, phosphorylase, esterase, myofibrillar ATPase 
reaction at preincubation pH of 9.8, 4.5, and 4.3, reduced nicotinamide adenine 
dinucleotide-tetrazolium reductase, succinic dehydrogenase, acid phosphatase, and oil red 
O.  
 Specimens from the radial and peroneal nerves were immersion fixed in 2.5% 
glutaraldehyde in 0.1M phosphate buffer before shipment to the laboratory. Upon receipt, 
nerves were post-fixed in 1% aqueous osmium tetroxide for 3h to 4h and then dehydrated 
in a graded alcohol series and propylene oxide. After infiltration with a 1:1 mixture of 
propylene oxide and araldite resin for 4h, nerves were placed in 100% araldite resin 
overnight and then embedded in fresh araldite resin. Thick sections (1µm) were cut and 
stained with paraphenylediamine prior to light microscopic evaluation.   
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 For immunohistochemical localization of motor end-plates, serial cryosections 
(8µm) were obtained from the external intercostal muscle of 1 affected Labrador 
Retriever, archived frozen muscle of a previously diagnosed Jack Russell Terrier with 
CMS due to AChR deficiency (neuromuscular disease control), and a normal dog (wild-
type control). Sections from each dog were incubated with the esterase reaction for 
identification of presumptive motor end-plates or Alexa Fluor 594 α-bungarotoxin 
(1:1000, Molecular Probes) for localization of AChRs at the motor end-plate. Serial 
sections were evaluated with light microscopy (esterase reaction) and fluorescent 
microscopy (red fluorescence) and localization of stainings compared.  
  
AChR Quantification and Antibody-bound AChR 
 AChR was extracted from external intercostal muscle specimens of both affected 
puppies by a procedure modified from that of Lindstrom and Lambert [21]. The muscle 
specimens were stored at -70ºC prior to homogenization and extraction of AChR in 2% 





I-αbgt) followed by sequential addition of high titer rat-anti-AChR 
antibody and precipitation with goat anti-rat IgG. The precipitate was pelleted, washed, 
and quantitated in a gamma counter. The amount of AChR complexed with 
125
I-αbgt was 
quantified and expressed in terms of moles of 
125
I-αbgt precipitated per gram of tissue. 
The concentration of in-situ antibody-AChR complexes was determined by precipitation 
with goat anti-rat serum in the presence of normal rat serum. Quantitative serum AChR 
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antibody concentrations were determined as previously described using an 
immunoprecipitation radioimmunoassay procedure [22]. 
 
SNP Profiling 
Eighteen candidate genes were selected based on their involvement in human 
CMSs. Candidate genes were distributed across 13 canine chromosomes: 3 (DOK7), 5 
(AGRN, CHRNB1, CHRNE, DPAGT1), 6 (ALG14), 9 (SCN4A), 10 (GFPT1), 11 (ALG2, 
MUSK), 13 (PLEC1), 18 (RAPSN), 20 (LAMB2), 23 (COLQ), 25 (CHRNG, CHRND), 28 
(CHAT), and 36 (CHRNA1) [1]. The Illumina CanineHD Infinium BeadChip was used to 
profile 173,662 SNPs representing all chromosomes for 9 nuclear family members: 7 
littermates and both parents (Figure 1). Arrays were processed according to 
manufacturer’s protocols. Allele frequencies were calculated using a case/control analysis 
conducted with PLINK [23]. Chromosomal regions harboring candidate genes were 
evaluated for SNP haplotypes with frequencies of 1.0 in the CMS cases and between 0.14 
and 0.50 in the controls. Individual genotypes in regions fitting these parameters were 
then manually examined to ensure that no unaffected littermates were homozygous for 





Figure 1. Multigenerational pedigree of Labrador Retrievers. Filled individual icons 
denote affected dogs and semi-filled icons denote obligate carriers. Asterisks mark 
individuals selected for whole-genome SNP profiling. 
 
Microsatellite Analysis 
PCR for amplification of individual microsatellite markers was performed using 
materials and thermal cycling parameters previously described [24,25]. Products were 
resolved with GeneScan 600 LIZ size standard (Applied Biosystems) on an ABI 3730XL 
DNA Analyzer (Applied Biosystems). GeneMapper Software version 4.0 (Applied 
Biosystems) was used to visualize the microsatellite signals. 
 
Sanger Sequencing 
Primers were designed to amplify all coding regions and splice sites of CHRNG, 
CHRND, and COLQ. Products were amplified using ReddyMix Master Mix (Thermo 
Scientific) with 0.4µM of each primer and 50ng of DNA. Products were purified using 
the Qiax II Gel Extraction Kit (Qiagen) or an ExoSAP master mix consisting of 0.5 units 
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of Exonuclease I (New England BioLabs) and 0.25 units of SAP (Promega). Primer 
sequences and purification methods for each amplicon are given in Table S1. Sequencing 
products were resolved on an ABI 3730XL DNA Analyzer (Applied Biosystems).  
 
Restriction Enzyme Digest 
 Detection of the COLQ variant was accomplished using the endonuclease BtsI, 
which recognizes the following sequence and cutsite (^): 5’…NN^CACTGC…3’. The 
digestion was performed using BtsI CutSmart (New England BioLabs) with 2.5μL 10X 
buffer, 0.40μL BtsI, 1μg DNA, and water adjusted accordingly for a total reaction 




 Neurological examination was consistent with a generalized neuromuscular 
disease with marked short-strided tetraparesis that worsened with exercise. Postural 
reactions were preserved with the exception of hopping which was diminished in all 
limbs when the puppies were made to bear full weight. Spinal reflexes including the 
patellar, cranial tibial, and flexor withdrawals were reduced in all limbs. A 







 EMG was performed on the left side of the body and included the supraspinatus, 
infraspinatus, triceps, biceps, extensor carpi radialis, superficial and deep digital flexor, 
interosseous, biceps femoris, rectus femoris, cranial tibial, and gastrocnemius muscles. 
Abnormal EMG activity was not identified in any muscle group.  Peroneal and ulnar 
MNCV was likely age appropriate (41m/sec and 31m/sec, respectively; reported values 
for normal dogs 1 to 6 months of age 32m/sec to 55m/sec and 25m/sec to 48m/sec) 
[26,27]. The peroneal and ulnar nerve CMAP amplitudes were reduced at all stimulus 
sites (1.9mV to 2.1mV and 2.6mV to 2.9mV, respectively, reference ≥8mV, peak-to-
peak) (Figure 2) [27].  F-waves were not recordable upon stimulation of either the 
peroneal or ulnar nerve.  Repetitive stimulation of the peroneal nerve revealed a 
decrement in the CMAP amplitude of 22% at 2Hz, 33% at 5Hz, and 35% at 50Hz when 
the first and third CMAPs were compared (Figure 3). Decrements greater than 10% are 




Figure 2.  Peroneal MNCV of an affected Labrador Retriever recorded at the extensor 
digitorum brevis muscle with stimulation at the level of the hock, stifle, and hip.  
Although the CV was normal considering the dog’s age, the amplitude of the CMAP was 
uniformly diminished. The timebase between vertical columns on the x-axis is 2msec and 
the voltage measured between adjacent rows on the y-axis is 2mV.  Control tracings are 
from the peroneal nerve of a healthy 5 month old Beagle. Note: labeling varies with the 
control amplitudes measured from baseline to peak, peak-to-peak amplitudes are within 




 Figure 3.  Repetitive stimulation of the peroneal motor nerve of an affected Labrador 
Retriever at 2Hz (A), 5Hz (B), and 50Hz (C).  Decrement of the CMAP was observed at 
all tested frequencies. Sweep speed and sensitivity settings are identical to those in Figure 
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2.  Control tracings are from the peroneal nerve of a healthy 5-month-old Beagle with no 
decrement seen at low frequency stimulation and normal pseudofaciliation (CMAP gets 
taller and narrower) with tetanic stimulation. 
 
 
Histopathology, Histochemistry, and Immunohistochemistry 
 Myofiber size was appropriate in all muscles evaluated and no specific 
abnormalities were identified, making a congenital myopathy unlikely.  Multifocal areas 
of esterase reactivity were identified, but it could not be determined from this reaction if 
staining correlated with localization of motor end-plates. In the Labrador Retriever with 
CMS, esterase staining was evident in multiple locations but did not fully correlate with 
AChR labeling (Figure 4).  There was a good correlation with esterase staining and 
AChR labeling in the normal dog.  In the Jack Russell Terrier with CMS (neuromuscular 
disease control), several end-plates were stained with esterase; however, no AChRs were 
labeled in the serial muscle section, consistent with the marked decrease in muscle 
AChRs described in this breed. There was no evidence of axonal degeneration, 
demyelination, or abnormalities of supporting structures in the peripheral nerve 




Figure 4. Cryosections (8µm) of intercostal muscle from a normal dog, a Labrador 
Retriever with CMS (end-plate AChE deficiency), and a Jack Russell Terrier with CMS 
due to AChR deficiency (neuromuscular disease control) are illustrated. For each dog, 
histochemical staining for esterase activity (brown stain) is shown along with a serial 
section demonstrating immunofluorescent localization of α-bungarotoxin for AChR and 
end-plate localization (red color). Muscle nuclei are blue (Dapi stain). There is a good 
correlation between esterase staining (brown) and α-bungarotoxin localization (red) in the 
control dog muscle. Although esterase staining is present in the Labrador Retriever 
muscle (arrows), the localization correlates poorly with that of AChRs.  In the CMS Jack 
Russell Terrier esterase staining was present; however, staining for AChR was markedly 
decreased or absent, consistent with a markedly decreased AChR content. Bar = 50µm 




AChR Quantification and Antibody-bound AChR 
 The concentration of AChR was determined from external intercostal muscle 
samples collected origin to insertion following euthanasia of both affected Labrador 
Retriever puppies. The AChR concentration was decreased in both puppies (0.07pmol/gm 
and 0.10pmol/gm tissue, reference 0.2pmol/gm to 0.4pmol/gm).  AChR antibodies were 
not detected bound to muscle AChRs or in the serum.  
 
Analysis of Family Genomic Inheritance Patterns 
 Over 172,000 SNPs across 40 canine chromosomes were genotyped for each of 9 
nuclear family members. Allele frequencies in regions on the 13 chromosomes harboring 
candidate genes were evaluated for a pattern consistent with a recessive trait (Table S2). 
SNP haplotypes on both chromosomes 23 and 25 were homozygous in the cases and had 
frequencies of 0.36 and 0.29, respectively, in the unaffected individuals. Chromosome 23 
harbors COLQ, while the region on chromosome 25 includes both CHRNG and CHRND.  
Because the sire and dam share 2 recent common ancestors, we hypothesized that 
the causative mutation was inherited identical by descent (IBD). To determine whether 
the aforementioned segments of chromosomes 23 and 25 were inherited IBD, we 
genotyped polymorphic microsatellite markers in each region. Genotypes revealed 
homozygosity in the affected dogs for markers flanking COLQ, providing evidence that 
the segment on chromosome 23 is IBD (Figure 5). Affected dogs were heterozygous for 
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haplotypes encompassing CHRNG and CHRND, suggesting that the chromosome 25 
segment was not inherited from a recent common ancestor. 
 
Figure 5. Microsatellite and SNP haplotypes (color-coded bars below individuals) are 
shown for 3 candidate genes. Positions (in Mb) are according to CanFam 2. Filled 
individual icons denote affected dogs and semi-filled icons denote obligate carriers. 
Chromosome 23 haplotypes (blue) are inherited IBD in both affected dogs. 
 
Sequencing of CHRNG, CHRND, and COLQ 
 No nonsynonymous variants were identified in CHRNG. A single 
nonsynonymous variant in exon 4 of CHRND did not segregate with a recessive 
phenotype. Sequence data for COLQ revealed 3 nonsynonymous variants, only 1 of 
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which segregated with a recessive trait. The exon 14 variant, c.1010T>C, predicts the 
substitution of isoleucine with threonine at residue 337 (Figure 6A). 
 
Screening of c.1010T>C Variant 
 PCR amplicons from the COLQ exon 14 primer set are 470bp in size. BtsI cleaves 
the amplicon only in individuals having the c.1010T>C allele, yielding fragments of 
204bp and 266bp. Heterozygotes for the variant have all 3 fragments sizes (Figure 6B).  
Digestion with Bts1 was used to genotype the variant for 49 additional members 
of this Labrador Retriever family, 288 unrelated Labrador Retrievers, and 112 dogs 
representing 65 other breeds (Table S3). Of the 58 family members, 40 were homozygous 
wild-type, 16 were heterozygous, and only the 2 affected dogs described herein were 
homozygous for the variant. The variant was not present in any unrelated Labrador 




Figure 6. (A) Sequence from the 5’ end of the C-terminal domain of ColQ in mammals. 
Identical residues are denoted by an asterisk, conserved substitutions by a colon, and 
semi-conserved substitutions by a period. Residues altered in human CMS cases are 
highlighted in yellow [4,30,32,37]. (B) BtsI digest results for the Labrador Retriever 
family. PCR amplicons from COLQ exon 14 are 470bp in size and cleaved into 204 and 
266bp fragments in the presence of c.1010T>C. Three clinically normal littermates were 
identified as carriers, denoted by semi-filled icons. 
 
Discussion 
 The probands in this study presented with an early onset neuromuscular disorder 
characterized by severe exercise-induced weakness. The lack of specific morphological 
changes in muscle and peripheral nerve biopsies excluded an underlying congenital 
myopathy or neuropathy. Electrodiagnostic findings and decreased AChR concentration 
in the muscle indicated a disorder of neuromuscular transmission. The autoimmune 
disease myasthenia gravis was eliminated based on the early age of onset and an absence 
of AChR antibodies in serum and AChR-bound antibodies in the muscle. The clinical 
diagnosis in the Labrador Retrievers was CMS. 
While clinical signs and electrophysiological findings are generally similar 
between presynaptic, synaptic, and postsynaptic forms of CMS, a notable observation in 
the affected puppies was a worsening of the phenotype upon administration of an AChE 
inhibitor. This response indicates desensitization of the AChRs from overexposure to 
ACh and is consistent with a synaptic form of CMS referred to as end-plate AChE 
deficiency (EAD) [5]. EAD accounts for 10% to 15% of all human cases of CMSs and is 
always caused by mutations in COLQ [5]. COLQ encodes a collagen strand that 
homotrimerizes to form the tail subunit of asymmetric AChE. ColQ anchors AChE to the 
basal lamina where the enzyme hydrolyzes ACh, thereby limiting the length of the 
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synaptic response [28]. In the absence of ColQ, ACh accumulates, causing prolonged 
muscle contraction and eventually the desensitization of AChR [29].  
Through the examination of SNP allele frequencies in the Labrador Retriever 
family, we identified 2 chromosomes harboring CMS candidate genes that showed an 
inheritance pattern consistent with autosomal recessive transmission. Whereas human 
forms of CMS are often caused by compound heterozygosity, low levels of genetic 
diversity within purebred dog populations make simple recessive alleles more common. 
Linebreeding in this Labrador Retriever family makes it likely that the sire and dam 
inherited the mutation from a common ancestor and that the affected puppies are 
homozygous for a chromosome segment transmitted IBD. Analysis of polymorphic 
microsatellites showed that the regions flanking COLQ are IBD, whereas those flanking 
the other 2 identified candidate genes are not.  
Sequencing of COLQ in the Labrador Retrievers revealed a missense mutation 
that predicts the replacement of a conserved hydrophobic isoleucine with a hydrophilic 
threonine in the C-terminal domain. ColQ has 3 domains: an N-terminal proline-rich 
attachment domain (PRAD), a collagenic central domain, and a C-terminal domain. The 
PRAD serves to attach the ColQ strand to an AChE tetramer. The collagen domain 
assembles the triple helix, while the C-terminal domain is involved in both the formation 
of the triple helix [30] and anchoring of the structure to the basal lamina [30,31]. 
 In humans, mutations responsible for EAD have been identified in each domain of 
COLQ and have different functional consequences depending on their location [4]. In the 
C-terminus, missense mutations in residues ranging from positions 342 to 452 are 
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thought to inhibit the attachment of ColQ to the basal lamina of the muscle cell [30-33]. 
Some C-terminus mutations (e.g., V322D) may prevent the formation of the ColQ triple 
helix [32]. In the affected Labrador Retrievers, localization of the esterase reaction 
showed a poor correlation between AChE and AChR. This finding suggests improper 
anchoring of ColQ to the basal lamina, or mislocalization. Insufficient muscle samples 
prevented us from conducting a sedimentation profile of AChE to determine the exact 
consequence of the I337T mutation identified.   
Linebreeding practices expedite the appearance of recessive diseases in purebred 
dog populations. The availability of genetic tests for the detection of carrier dogs allows 
for selective breeding to prevent widespread dissemination of the deleterious allele to the 
breed while maintaining genetic diversity. Because only 2 affected littermates were 
available for study herein, GWAS techniques could not be applied. The analysis of 
chromosomal inheritance patterns indicated a single functional and positional candidate 
gene and led to the discovery of the COLQ c.1010T>C mutation; however, our approach 
does not exclude the possibility that another mutation exists in a novel CMS gene.  
While this manuscript was in revision, Matlik et al. reported that an identical 
mutation (c.1010T>C; I337T) was homozygous in 2 human CMS patients with EAD 
[34]. The affected children were first cousins from consanguineous relationships; both 
sets of parents were heterozygous for the mutation [34]. The substitution was the only 
variation identified in COLQ and was determined to be pathogenic through a prediction 
program [34]. Although uncommon, identical changes at the DNA level between humans 
and dogs with similar phenotypes have been previously identified [35,36]. The 
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identification of c.1010T>C in humans and dogs diagnosed with CMS strongly supports 
the causality of the mutation and shows that conservation of residue 337 is critical for 
proper function of ColQ.  
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Please refer to Appendix One: Supplementary Material for Chapter Two. 
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Abstract 
Congenital myasthenic syndromes (CMSs) are a group of neuromuscular 
disorders that result from the disruption of transmission across the neuromuscular 
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junction (NMJ). As part of this signaling, acetylcholine (ACh) travels across the synaptic 
cleft and binds to the acetylcholine receptors (AChRs) on the post-synaptic membrane. 
Over half of reported CMS cases in humans involve mutations in the genes encoding the 
subunits of the AChR. While most published cases are human, CMSs have been reported 
in a few dog breeds, including the Jack Russell Terrier (JRT).  CMS with an early onset 
of generalized weakness and exercise intolerance was described in JRTs in the 1970s, but 
has not been characterized at the molecular level. Immunohistochemistry showed a 
deficiency of AChRs in JRT CMS, and the genes that encode the 5 subunits of the AChR 
were selected as candidate genes. Microsatellite alleles were utilized to determine 
haplotypes for the chromosomal regions surrounding each of the 5 genes encoding the 
subunits. Haplotypes flanking CHRNB1 and CHRNE, located adjacent to each other on 
chromosome 5, segregated with the CMS phenotype in a JRT family. Sequences of the 
splice sites and exons from both genes revealed a single base insertion in exon 7 of 
CHRNE (G193RfsX272) that is homozygous in affected JRTs and heterozygous in 
obligate carriers. The insertion was not detected in 245 unrelated JRTs. Herein, we 
describe the genetic cause of CMS in the JRT. 
 
Introduction 
Contraction of skeletal muscles is triggered by signaling across the neuromuscular 
junction (NMJ) and involves several proteins. In general, acetylcholine (ACh) is 
produced in the motor neuron, travels across the synapse, and activates muscle 
contraction by binding to the acetylcholine receptors (AChRs). The excess ACh is then 
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broken down by acetylcholinesterase (AChE), terminating the signal for muscle 
contraction [1]. Mutations in the genes that encode proteins involved in this signaling 
pathway and disrupt the transmission across the NMJ can result in congenital myasthenic 
syndromes (CMSs).  
In approximately 50% of human cases, causative mutations are identified in one 
of the subunits of the AChR [2]. Most CMSs are inherited in an autosomal recessive 
manner, and compound heterozygosity is often observed [2-5]. While the specific 
symptoms vary depending upon the compromised protein [2], generalized skeletal muscle 
weakness is the most common clinical sign.  
 While rare, cases of CMS are observed in other animals, including cows [6] and 
dogs [7-12]. These cases appear to be familial and clinical signs usually present when the 
animals are between 6 and 12 weeks old, with severe and widespread weakness of the 
skeletal muscles as the most common clinical sign. The first report of CMS in the dog 
was in 1974 in a Jack Russell Terrier (JRT) [7]. Clinical signs were first noted at 8 weeks 
of age, beginning with rapid fatigue onset [7]. The dog responded to anticholinesterase 
medication, and a month-long increase in muscle strength was achieved [7]. Two half-
siblings (same sire) also showed clinical signs including fatigue after exercise, one at 5 
weeks of age and another at about 6 to 7 weeks of age [7]. Four years later, another case 
of CMS in this breed was reported, and the clinical signs were described as a progressive 
weakness affecting the limbs that was exacerbated by exercise and responded well to 
anticholinesterase drugs [13]. Immunohistochemistry studies in affected tissues indicated 
that JRTs with CMS have an endplate AChR deficiency [14]. CMS in JRTs is consistent 
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with an autosomal recessive inheritance [15]. While CMS has afflicted the JRT for at 
least 40 years, cases are sporadic and the causative mutation has yet to be identified. 
Here, we describe recent cases of CMS in JRTs with investigation into the genetic cause 
of this disorder.   
 
Materials and Methods 
Animals 
 Two intact male 7-week-old JRT puppies were presented to the Ontario 
Veterinary College (OVC) Neurology Service for evaluation of generalized weakness. Of 
seven puppies in the litter, six survived birth. The dams of both dam and sire were 
reported to be full sisters. The breeder noted that the puppies appeared normal until 
approximately six weeks of age when one puppy started to show signs different from the 
other littermates.  The puppies responded dramatically to the short-acting 
anticholinesterase drug edrophonium chloride and then to the longer-acting 
anticholinesterase drug pyridostigmine bromide. After 6 weeks of treatment, drug 
resistance developed and the pups were humanely euthanized.  
 
Electrophysiology 
 Electrodiagnostics were performed on both affected puppies and included 
electromyography (EMG), measurement of motor nerve conduction velocity (MNCV), 
and measurement of the decrement in the compound muscle action potential (CMAP) 
following repetitive nerve stimulation. Studies were performed on the left side under 
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general inhalational anesthesia using a Nicolet Viking Select EMG/evoked potential 
system (Nicolet, Biomedical Inc.). Insulated stainless steel needle electrodes were used 
for both nerve stimulation and recording from muscle, while a platinum subdermal 
electrode (Grass-Telefactor) was employed as a ground.  MNCV of the peroneal and 
ulnar nerves was determined by dividing the distance between proximal and distal 
stimulation sites by the difference in latency of the corresponding CMAP recorded from 
the extensor digitorum brevis muscle and palmar interosseous muscles, respectively, after 
supramaximal stimulation (2Hz stimulus rate, 0.2ms stimulus duration). Amplitude (peak 
to peak) was measured from CMAPs derived from stimulation at the proximal and distal 
stimulation sites. Repetitive nerve stimulation parameters included stimulation 
frequencies of 1, 2, 3, 5, 10, 20, or 50Hz. 
 
Sample Collection and Nucleic Acid Isolation 
 Whole blood was drawn from the 2 affected puppies, an unaffected sibling, and 
the dam of a JRT family by clinicians at the OVC. Informed owner consent and all 
samples were obtained in accordance with protocols approved by the University of 
Guelph Institutional Review Board. Blood was unavailable from the deceased sire. 
Additional JRT DNA samples collected for unrelated  studies were provided by the 
Veterinary Medical Diagnostic Laboratory of the University of Missouri. Left ventricle 
tissue from an affected JRT from Florida was obtained. Tissue samples collected during 
the studies performed by the Mayo Clinic [14,16] were also provided. Limb muscle 
samples were obtained from the 2 affected puppies. Genomic DNA was isolated from the 
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tissues using the Gentra Puregene DNA Extraction Kits (Qiagen). RNA was isolated 
from limb muscle tissues and from the left ventricle tissue from the affected Florida JRT 
using the ISOLATE RNA Mini Kit (Bioline). 
 
AChR Quantification and Antibody-Bound AChR 
 AChR was extracted from external intercostal muscle specimens of both affected 
puppies by a procedure modified from that of Lindstrom and Lambert [17]. The muscle 
specimens were stored at -70ºC prior to homogenization and extraction of AChR in 2% 





I-αbgt) followed by sequential addition of high titer rat-anti-AChR 
antibody and precipitation with goat anti-rat IgG. The precipitate was pelleted, washed, 
and quantitated in a gamma counter. The amount of AChR complexed with 
125
I-αbgt was 
quantified and expressed in terms of moles of 
125
I-αbgt precipitated per gram of tissue. 
The concentration of in-situ antibody-AChR complexes was determined by precipitation 
with goat anti-rat serum in the presence of normal rat serum. Quantitative serum AChR 
antibody concentrations were determined as previously described using an 
immunoprecipitation radioimmunoassay procedure [18].  
 
Microsatellite Analysis 
 Microsatellite markers flanking the candidate genes (Table 1) were amplified 
using protocols described by Clark and colleagues [19], with the exception that each 
microsatellite was amplified individually. Products were resolved on an ABI 3730XL 
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DNA Analyzer (Applied Biosystems) with GeneScan 600 LIZ size standard (Applied 
Biosystems). Microsatellite signals were visualized using GeneMapper Software version 
4.0 (Applied Biosystems). 
 












Table 1. Microsatellite markers flanking candidate genes. 
 
Sequencing of CHRNB1 and CHRNE 
 Primers were designed to amplify the splice sites and coding regions of CHRNB1 
and CHRNE (Table 2). PCR amplification of one of the affected puppies and the dam of 
the products was performed with ReddyMix Master Mix (Thermo Scientific) using 
primers at a concentration of 0.4µM and 50ng of DNA. ExoSAP-IT (Affymetrix) was 
used according to the manufacturer’s instructions to purify the products. Sequencing 


















1 CAGGAGACCATAAAGGGAAGG CTTTACTGGTTGCTCTTCTCCTC 
2 TCACTGAGCAACCAACCG CATCGGGTCGGGAAATAACG 
3 TGAGATAGAGGTGGGGCTTACA CCCTCCTCGTTTTTAGACCCAA 
4&5 GCCGTAATCAGAACTCCGAC CTTCTCTGTCCACTGTCACTG 
6 CCTCTCCTGAAACACTGACTCC GGTGGGCAAGATGAGTGAGAAT 
7 CAAGTTCACCAGAGATGGGCTA TACTGCCCTCTTCTCTCCATCC 
8 CACTGATTGTGCCACGAAAA GTCAGGTTCTATCAGGGTGG 
9 TTCTTCGTCCATACTGCCCATTCT GCAGAGGCAGGCGGCTTA 
10 GCAGAGGCAGGCGGCTTA GCCCCTGTCTTCCGACTGG 






1&2 TAGATGACAGTCCCCTAACCCG TGGAATCGTGAGTGAGAGCC 
3&4 CAGACACACGGAGCAGCG AACTGCTCGCTGGTCTTCCG 
5&6 TGTGCTGGAGAACAAGTGAGG CATCATCTACACGCTCATCATCC* 
7 GGCGAGACCATCAGCAAAATC CCGTCTTCCTGTTCCTGA 
8 TGCTGCTCGCCTACTTCCTGC TGGAGGCGGAGTCAGGAGCAC 
9&10 GAAGAGGGAGCACCGAGC CTCCCTCTCTCCCTCGCTC 
11&12 CTGGACTGGTGAGCCGAGGG AGTTGCGTGTGCGTGCGG 
Table 2. Primers (5'-3') for amplification of CHRNB1 and CHRNE. Primers were 
designed to amplify the splice sites and coding regions of CHRNB1 and CHRNE.  
*A separate reverse primer was designed to sequence exon 6 of CHRNE:  
5'- CCGTCCCTCCCACCCCTT -3' 
 
 
cDNA Synthesis and PCR Amplification 
cDNA was synthesized using the SensiFAST cDNA Synthesis kit (Bioline) as per 
the manufacturer’s instructions. Primers were designed to capture the insertion in exon 7 
of CHRNE (forward primer: 5’- CAATGCCGAGGAGGTGGA -3’ and reverse primer: 
5’- CTGTGTCATCGTGCTCAACG -3’) and products were amplified using ReddyMix 
PCR Mastermix (Thermo Scientific). PCR products were run on a ~1.3% agarose gel. 
ExoSAP-IT (Affymetrix) was used according to the manufacturer’s instructions to purify 







  Affected JRT puppies showed an onset of generalized muscle weakness at 7 
weeks of age and could walk only briefly for 10-15 short-strided steps before having to 
sit or lay down. After a brief rest, both puppies would rise and resume activity.  
Regurgitation was not noted by the caregivers and lateral thoracic radiographs of both 
puppies did not show a dilated esophagus. Based on results of physical and neurological 
examinations, the cause of the muscle weakness was localized to the neuromuscular 
junction.  
 An edrophonium chloride challenge (short acting anticholinesterase drug, 0.1-
0.2mg/kg IV) was performed as a presumptive test for myasthenia gravis and results 
recorded (see video). Both puppies responded immediately with a return to almost normal 
activity levels for approximately 3-5 minutes. The long-acting anticholinesterase drug 
pyridostigmine bromide (12mg/ml, compounded by the OVC Pharmacy) was prescribed 
at 1 mg/kg orally every 12 hours. Both puppies responded with improvement within an 
hour to almost normal activity levels. Over the following month, the dosage of 
pyridostigmine and the frequency of dosing had to be incrementally increased to maintain 
normal activity. By 6 weeks following initiation of treatment and with a pyridostigmine 
dosage of 1.5 mg/kg PO every 6 hours, the pups could only walk a dozen steps before 
sitting down to rest. Increasing the dose to 2mg/kg resulted in adverse effects including 
vomiting without improvement in exercise tolerance. Due to the poor prognosis for 
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recovery and lack of other specific treatment options, both pups were anesthetized for 
electrodiagnostic studies followed by humane euthanasia and tissue collection.   
 
Electrophysiology 
 Electromyography and measurement of motor nerve conduction velocities 
performed under general anesthesia in both puppies were normal. For puppy 1, 
measurement of the compound muscle action potentials following repetitive nerve 
stimulation was performed after having discontinued pyridostigmine overnight. 
Recordings showed 36.9% decrement between the first and fifth stimulation.  
Neostigmine (0.05 mg/kg IV) was administered and RNS recorded 2, 4, 6, 8, and 10 
minutes afterwards. Decrements were recorded to be 62.2%, 29.1%, 23.5%, 42.2%, and 
66% respectively.  For puppy 2, recordings showed a 48.2% decrement between the first 
and fifth response. Five minutes after 0.05mg/kg neostigmine IV, there was improvement 
to 41.1% decrement between first and fifth responses. Ten minutes after the neostigmine 
was administered, the decrement was recorded to be 63.4%.  Both puppies were 
humanely euthanized following examinations and post-mortem examinations and tissue 
collections performed.  
 
AChR quantification 
 The concentration of AChR was determined from external intercostal muscle 
samples collected origin to insertion following euthanasia of both affected JRT puppies. 
The AChR concentration was decreased in both puppies (0.03pmol/gm and 0.04 pmol/gm 
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tissue, reference 0.2pmol/gm to 0.4pmol/gm tissue).  AChR antibodies were not detected 
bound to muscle AChRs or in the serum.  
 
Post-Mortem Examination, Histopathology and Histochemistry 
 No indication of a primary nervous system or muscle disorder was found on post-
mortem examination.  Occasional groups of atrophic fibers of both fiber types was noted 
in frozen muscle sections that were considered consistent with functional denervation 
caused by the deficits in neuromuscular transmission in chronic  myasthenia gravis. 
 
Microsatellite Analysis 
 Because of the documented deficiency of AChRs by immunoprecipitation 
radioimmunoassay in the affected JRTs in this family as well as in other cases of CMS in 
Jack Russell Terriers [14], the genes encoding the 5 subunits of the AChR were identified 
as functional candidates: CHRNA1, CHRNB1, CHRNG, CHRND, and CHRNE. CHRNA1 
is located on canine chromosome (CFA) 36, CHRNB1 and CHRNE on CFA 5, and 
CHRNG and CHRND on CFA 25. 
 All markers were polymorphic in the JRT family, with 2-3 alleles. While 
haplotypes surrounding CHRNA1 segregate with an autosomal recessive inheritance, 
heterozygosity in the affected dogs does not support identity by descent (IBD). The 
haplotypes encompassing CHRNB1 and CHRNE were homozygous in affected 
individuals, consistent with IBD (Figure 1). Haplotypes surrounding CHRNG and 




Figure 1.  Microsatellite haplotypes flanking the AChR subunit genes. Microsatellite 
markers flanking the AChR subunit genes CHRNB1 and CHRNE were amplified. The 
alleles were compiled into haplotypes for each member of the pedigree with the 
exception of the sire, whose alleles were extrapolated based on the alleles of the other 
members of the pedigree as no DNA sample was available. Colored bars represent 
haplotypes.  
 
Sequencing of CHRNB1 and CHRNE 
One exonic and 3 intronic variants were identified in CHRNB1, but none 
segregated with a simple recessive mode of inheritance (homozygous in the affected dog 
and heterozygous in the dam). Five exonic variants were identified in 3 exons of CHRNE, 
but only 1 fit the expected pattern of inheritance. Further investigation of this mutation 
revealed that the other affected puppy was homozygous for the mutation and the 
unaffected sibling did not possess it. The variant is an inserted C in exon 7 after position 
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576 of CHRNE (ε576insC) (Figure 2). Both affected dogs were homozygous for this 
insertion, the dam was heterozygous, and the unaffected sibling did not harbor the 
insertion. Four affected JRTs from the 1970s and 1980s studies as well as the affected 
dog from Florida were homozygous for the insertion. One obligate carrier was 
heterozygous. An additional 245 unaffected JRTs were screened, and none of them 
harbored the mutation (Table 3). 
 
Figure 2. Direct sequences from unaffected, carrier, and affected Jack Russell Terriers. 
(A) Wild-type sequence (B) Carriers of the G193RfsX272 allele have an extra C on only 
one chromosome, causing sequences to be offset by one base. (C) Affected dogs are 












Affected (7) 0 0 7 
Obligate Carrier (2) 0 2 0 
Unaffected (246) 246 0 0 
Table 3. Jack Russell Terriers genotyped for G193RfsX272. Of the two carriers, one is 
the dam of the two affected puppies discussed above, and the other is a known carrier 





 The cDNA PCR products were run on a gel to determine whether the cDNA of 
the affected dog could be amplified. Both the unaffected and affected dogs’ cDNA PCR 
produced a 470bp band on the gel (data not shown). An affected dog’s sequence showed 
that the insertion is included in the cDNA. 
 
Discussion 
 The CMS phenotype affecting JRTs is recessive, as neither of the parents was 
affected and there have been previous studies indicating that CMS is inherited as a 
recessive trait in JRTs [15]. Further, the parents of the affected puppies are cousins, 
indicating that the affected puppies are the result of linebreeding. In addition, because 
dog breeds are essentially closed populations, and because this disease appears to have 
been in this breed for some time [7,13-15], we believe that the variant of interest has been 
inherited IBD. Therefore, CHRNB1 and CHRNE were chosen as candidate genes for 
further analysis as the microsatellite allele haplotypes appeared to segregate with the 
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CMS phenotype in our JRT family and because the haplotypes indicated homozygosity 
(as opposed to compound heterozygosity) in the affected dogs.   
 Sequencing of the splice sites and coding regions of CHRNB1 and CHRNE 
revealed a homozygous C insertion in exon 7 of CHRNE (G193RfsX272) in both affected 
dogs. The dam was heterozygous, and the unaffected sibling did not harbor 
G193RfsX272. The insertion predicts a frameshift beginning at residue 213, with a 
premature stop codon after residue 485 (G193RfsX272) (Figure 3).  
 
 
Figure 3. Amino acid alignment of wild-type dog CHRNE and sequence with 




 The AChR is composed of 5 subunits: the alpha (α; CHRNA1), beta (β; 
CHRNB1), gamma (γ; CHRNG), delta (δ; CHRND), and epsilon (ε; CHRNE) subunits. 
Fetal AChR in muscle is comprised of 2 α subunits, 1 β subunit, 1 δ subunit, and 1 γ 
subunit. After week 31 of development, the γ subunit is replaced with an ε subunit, 
forming the adult AChR.  At the NMJ, ACh is released from the motor neuron and travels 
to the muscle cell, where it binds to the AChR at the α/δ and the α/ε interfaces [2].  The 
AChR then undergoes a conformational change involving all 5 subunits that begins the 
triggering of muscle contraction [2].  A mutation in any of the genes encoding these 
subunits can result in either the inability of the AChR to bind ACh, incomplete AChR 
pentamers, or the inability of the AChR to insert into the muscle cell. In humans, 
approximately 50% of all CMSs are the result of mutations in CHRNE [2].  
 Several human studies have identified frameshift mutations in the N-terminal of 
CHRNE [6,20]. One of these mutations, ε127ins5, predicts the conversion of codon 45 to 
a stop codon, resulting in truncation in the N-terminal domain [20]. Expression studies 
were performed that measured the amount of AChR expression as well as the number of 
α-bungarotoxin binding sites for both of these mutations [20]. The frameshift mutation 
had a reduced level of binding, similar to those of α2βδ2, the AChR pentamer that forms 
when the ε subunit is not incorporated into the pentamer [20]. The amount of ACh 
binding to the AChRs with ε subunits harboring the mutations was also measured, and 
again the results for the frameshift mutations were similar to that of the α2βδ2 pentamer 
[20]. Both showed a biphasic ACh-binding profile that has been credited to a lack of 
interaction that exists in the wild-type penatmer between the sites where ACh binds [20-
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22]. These results indicated that the ε127ins5 and ε553del7 mutations inhibit the 
incorporation of the ε subunit into the pentamer [20].  
 A later study found that the ε553del7 mutation causes the skipping of exon 6 [23]. 
In addition, they found that weak splicing signals at exon 6 were the cause of exon 
skipping in the normal transcripts they tested and that normally spliced mRNAs from the 
ε553del7 transcript as well as the skipped exon 6 mRNAs from the normal transcript 
were most likely being eradicated by nonsense-mediated mRNA decay [23]. It is likely 
that G193RfsX272 results in either the inability of the ε subunit to incorporate into the 
AChR pentamer [20] or causes the skipping of an exon [23]; however, further tests would 
be required to produce support for either possibility.  
  Due to the similarities between the phenotypes of the recent affected JRTs and 
those from the 1980s studies [14,16] and because CMSs are rare, we hypothesized that 
the affected dogs from the previous studies shared G193RfsX272 identified in our family. 
JRTs are not recognized as a breed by the AKC, so the breed standards are not as strict, 
resulting in more diversity in the JRT than in AKC-recognized breeds. As this mutation 
has been segregating in the breed for about 40 years, it is likely that the CMS phenotype 
only appears as a result of linebreeding. 
 In the future, the test described here can be used by those who use linebreeding to 
screen other JRTs in order to determine whether they carry G193RfsX272. Breeders can 
then make informed decisions, mainly avoiding the breeding of 2 carriers. Screening and 
careful breeding practices should result in a lower incidence of this disease in this breed 
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 The German Shepherd Dog (GSD) is a popular working and companion breed for 
which over 50 hereditary diseases have been documented. Herein, SNP profiles for 197 
GSDs were generated using the Affymetrix v2 canine SNP array for a genome-wide 
association study to identify loci associated with four diseases: pituitary dwarfism, 
degenerative myelopathy (DM), congenital megaesophagus (ME), and pancreatic acinar 
atrophy (PAA). A locus on Chr 9 is strongly associated with pituitary dwarfism, and is 
proximal to a plausible candidate gene, LHX3. Results for DM confirm a major locus 
encompassing SOD1, in which an associated point mutation was previously identified, 
but do not suggest modifier loci. Several SNPs on Chr 12 are associated with ME and a 
4.7 Mb haplotype block is present in affected dogs. Analysis of additional ME cases for a 
SNP within the haplotype provides further support for this association. Results for PAA 
indicate more complex genetic underpinnings. Several regions on multiple chromosomes 
reach genome-wide significance. However, no major locus is apparent and only two 
associated haplotype blocks, on Chrs 7 and 12, are observed. These data suggest that 




Shepherds and hounds were the first dog breeds developed to serve in specialized 
roles [1]. The German Shepherd Dog (GSD), for which a breed standard was originally 
developed in 1899, was bred for utility and intelligence and to be a multi-purpose servant 
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of humans [1]. Aptitude, temperament, structural efficiency, and other natural skills were 
deemed more important than aesthetic traits. Today, the GSD is among the most common 
breeds trained by the military, law enforcement, and service/assistance programs [2]. The 
GSD is also an extremely popular companion dog breed, ranking second in breed 
registration statistics reported by the American Kennel Club in 2010. Unfortunately, 
despite a large population size, more than 50 hereditary diseases have been described for 
the GSD [3]. 
Pituitary dwarfism is a rare disease of the GSD and is characterized by an 
abnormally small body stature because of a deficiency in pituitary growth hormone. Dogs 
appear to be normal at birth, but signs of stunted growth are usually evident by two to 
three months of age. There are no treatments available and lifespan is usually 
significantly shortened. Pituitary dwarfism in the GSD is inherited in an autosomal 
recessive fashion [4]. Combined pituitary hormone deficiency (CPHD) in humans is a 
type of growth hormone deficiency that results from a decrease in several hormones 
necessary for pituitary development. Mutations that cause congenital CPHD in humans 
have been identified in genes encoding several transcription factors important for 
pituitary development. These include PIT1, PROP1, LHX3, LHX4, and HESX1 [5]. In 
contrast, sequencing in affected GSDs of PIT1 [6], PROP1 [7], LHX4 [8], and LIFR [9], 
did not reveal any causative variants.    
Degenerative myelopathy (DM) is a late-onset neurodegenerative disease 
characterized by ataxia and weakness in the hind limbs. Symptoms of DM worsen over 
time, either steadily or in phases, and eventually result in complete paraplegia. In some 
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cases, DM may progress up the spinal cord and cause forelimb weakness or even 
respiratory difficulties [10]. The age of onset of DM is generally between 5 and 14 years, 
with a mean age of onset of 9 years [11]. The clinical signs observed in DM are general 
indicators of spinal cord disorders, but a definitive diagnosis for DM can only be made by 
histopathological examination of spinal cord tissue postmortem [12].  Most owners of 
affected dogs elect euthanasia within several months of symptom onset [13]. DM is most 
prevalent in the GSD [12]. A recessive missense mutation in SOD1 is associated with 
DM in several breeds, including the GSD [14]. DM has been proposed to be an animal 
model for amyotrophic lateral sclerosis (ALS). Approximately 20% of hereditary ALS 
cases are attributed to mutation of SOD1 [15]. 
Congenital idiopathic megaesophagus (ME) is characterized by dilation and 
hypomotility of the esophagus. The result of these abnormalities is regurgitation several 
minutes to hours after eating. Regurgitation episodes may occur as often as several times 
a day or as infrequently as once every few days. Symptoms for congenital ME typically 
begin around five weeks of age after weaning onto solid food. Affected puppies are 
malnourished, show a general failure to thrive, and are at risk for aspiration pneumonia. 
Diagnosis of ME is achieved by standard thoracic radiographs and/or fluoroscopy 
(barium swallow) [16]. ME is typically treated by feeding a high calorie, liquid diet from 
a raised dish [16]. Mortality is high in affected neonates. Many survivors require lifelong 
management of the disorder, but other cases resolve by four to six months of age [17]. 
ME is prevalent in the GSD, Great Dane, Miniature Schnauzer, Rhodesian Ridgeback, 
Dachshund, and Wire Fox Terrier, and is also reported to occur at lower frequencies in 
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many other breeds [18]. Several loci are thought to be responsible for ME in the dog [17]. 
The mode of inheritance in the GSD has not been investigated. 
Pancreatic acinar atrophy (PAA) is an autoimmune disease characterized by the 
selective atrophy of the acinar cells of the exocrine pancreas, which synthesize and 
secrete pancreatic digestive enzymes under physiologic conditions [19]. PAA is the most 
common cause of exocrine pancreatic insufficiency (EPI) in the dog [20] and is 
diagnosed through histopathologic examination [21]. EPI is diagnosed through the 
measurement of serum canine trypsin-like immunoreactivity (cTLI), with concentrations 
≤ 2.5 g/L considered as diagnostic [22]. By five years of age, 96% of affected dogs 
present with clinical signs of EPI, which include weight loss, increased appetite, and soft 
stools [20,23]. Affected dogs
 
can be treated with pancreatic enzyme supplements, 
although dogs with EPI are sometimes euthanized because of the expense associated with 
treatment or a poor response to treatment [24-25]. PAA is widespread in the GSD 
population, and affects other breeds including the Collie and Eurasian [26-27]. A recent 
test mating in the GSD shows that EPI is likely a polygenic disorder [28].  
 The development of high-throughput genotyping technologies has facilitated the 
discovery of genes responsible for simple and complex phenotypes of the dog [29-30]. 
The population structure of the dog is particularly well-suited for association mapping 
techniques because genetic bottlenecks during breed formation created large blocks of 
linkage disequilibrium within breeds [29]. Reported here is the use of a large cohort of 
GSDs to investigate the aforementioned four diseases that segregate in the population. 
Genetic profiles for 197 GSDs were generated using the Affymetrix v2 canine SNP array. 
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Using a single data set, we carry out genome wide association studies (GWAS) to 
identify risk loci for four diseases of the GSD.  
 
Materials and Methods 
Sample Collection 
Samples were recruited from individual owners from purebred GSDs that were 
diagnosed with EPI, DM, or ME through standard veterinary diagnostic practices. DM 
cases were diagnosed by veterinary neurologists. Dogs were considered to have 
congenital, idiopathic ME if they did not have conditions that can cause secondary ME, 
such as a persistent right aortic arch, myasthenia gravis, or hypoadrenocorticism. 
Purebred GSDs collected as healthy controls were ≥ 6 yrs and, to the owners’ knowledge, 
had no immediate family members affected with EPI, DM, or ME. Owners were asked to 
report all known hereditary conditions, as well as coat color phenotypes. Participants 
were recruited through breed clubs and listservs.  
Whole blood or buccal swabs were submitted by dog owners. Blood samples were 
collected by the primary care veterinarian of the dog. All samples were collected in 
accordance with protocols approved by the Clinical Research Review Committee (CRRC 
No. 07-04) at Texas A&M University and the Clemson University Institutional Review 
Board (IBC2008-17). Genomic DNA was isolated using the Gentra Puregene Blood Kit 
(Qiagen, Valencia, CA, USA). Serum samples were collected from all EPI cases and 
healthy controls and submitted to the Gastrointestinal Laboratory at Texas A&M 
University for measurement of serum cTLI concentration to confirm clinical status. 
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Concentrations ≤ 2.5 g/L were considered diagnostic for EPI. Control dogs had 
concentrations ≥ 5.7 g/L. All EPI cases were assumed to result from PAA, but tissue 
samples were not available to differentiate EPI due to PAA or another cause of EPI. 
 
GWAS 
SNP genotypes were generated using the Affymetrix v2 canine SNP array 
(http://www.broadinstitute.org/mammals/dog/caninearrayfaq.html). Arrays were 
processed at the National Human Genome Research Institute (NHGRI) or Clemson 
University Genomics Institute using the GeneChip human mapping 250K Sty assay kit 
(Affymetrix, Santa Clara, USA). All associated protocols were approved by the NHGRI 
Animal Care and Use Committee. The GeneChip human mapping 500K assay protocol 
was followed with a hybridization volume of 125 μl [29]. Raw CEL files were analyzed 
with the Affymetrix Power Tools software to obtain genotypes. SNPs having >10% 
missing data and ≥60% heterozygosity were removed from the dataset. Case/control 
analyses were performed on the 48,415 SNPs from the “platinum” set using PLINK [31], 
with Praw <0.0001 considered significant. To determine Pgenome values (EMP2), 
permutation testing (100,000) was performed for PAA, DM, and ME analyses using 
PLINK. A less conservative correction, Benjamini-Hochberg, was also performed [32]. 
Analysis of population stratification in 197 GSDs was conducted using identity-by-state 
clustering and multidimensional scaling in PLINK. The data, in a reduced representation, 




Genotyping of SNP 12.60274687 
Primers flanking the SNP 12.60274687 were designed: forward: 5'-
TGAGCACACAGAGGTGAGACAT-3' and reverse: 5'-
CAGTGGGAGGGTTTAGGAAGAGAT-3'. SNP 12.60274687 was amplified for 35 
additional ME dogs using Thermo ReddyMix (Thermo Fisher Scientific, Waltham, MA, 
USA) following the recommended protocol. Thermal cycling conditions were as follows: 
95°C for 15 min; 14 cycles of 95°C for 30 sec, 62°C for 1 min (decreasing 0.5°C each 
cycle), 72°C for 1 min; 20 cycles of 95°C for 30 sec, 55°C for 1 min, 72°C for 1 min; 
72°C for 10 min. PCR amplicons were analyzed by electrophoresis on agarose gels. 
Products were purified by adding 0.5 units Exonuclease I (New England Biolabs, Itswich, 
MA, USA) and 0.25 units of shrimp alkaline phosphatase (Promega, Madison, WI, USA) 
and incubating for 30 min at 37°C followed by 20 min at 80°C. Nucleotide sequencing 
was accomplished using the Big Dye Terminator version 3.1 Cycle Sequencing kit 
(Applied Biosystems, Carlsbad, CA, USA). Products were purified using Spin-50 mini-
columns with water (BioMax, Inc., Arnold, MD, USA) and resolved on an ABI Prism 
3730 Genetic Analyzer (Applied Biosystems). Sequences were analyzed to determine 
SNP genotypes. Odds ratios (OR), critical intervals and Chi-square tests were calculated 








Validation of methodology 
In total, 197 GSD samples were acquired from the United States, Canada, 
Germany, and the Netherlands. Two GSDs were affected with EPI and DM. One GSD 
was affected with EPI and ME. Principal component analysis using PLINK shows no 
evidence for population stratification within our GSD cohort (n=197), using all 
“platinum” SNPs (Fig. 1). To validate both our genotype data and statistical approach, we 
first mapped a positive control trait. Ten dogs in the study cohort had white coats, a 
recessive trait caused by the e allele of MC1R in the GSD [33]. GWAS using 197 GSDs 
(10 cases, 187 controls) reveals a strongly associated region encompassing MC1R on Chr 
5 (Fig. 2a). SNP 5.66900853, the most significant result (Praw = 3.61  10
-22
), is located 
approximately 208 kb adjacent to the E locus. The lack of subpopulations, combined with 





Figure 1. Principal component analysis of the GSD cohort shows all 197 dogs clustering 
together. The x-axis is principal component 1 and the y-axis is principal component 2. 
Two individuals that appear apart from the main grouping have the largest proportion of 




Four dogs in the control population had pituitary dwarfism. GWAS for these four 
cases versus 193 normal-sized controls shows a major region of association on Chr 9 
(Fig. 2b). Within this region, all four pituitary dwarfs are homozygous for a haplotype 
extending from SNP 9.52031784 to SNP 9.54102643. The haplotype is not observed in 
the homozygous state among the control dogs, however 15 control dogs were 
heterozygotes. The most significant association is for SNP 9.53350831 (Praw = 2.04  10
-
10





Figure 2. Manhattan plots showing the results for GWAS using 48,415 SNPs. The 
genome-wide P values (-log10 P) for each SNP are plotted against position on each 
chromosome. (a) Ten white GSDs versus 187 non-white GSDs show a strong association 
on Chr 5. (b) Four pituitary dwarf GSDs versus 193 normal-sized GSDs show a strong 







GWAS with 100,000 permutations for DM was carried out using all cases 
collected (n = 15) versus control dogs that were at least eight years of age and did not 
exhibit any clinical signs of DM (n = 69). The two strongest associations are with SNPs 
31.28909487 (Praw = 8.51  10
-06
, Pgenome = 0.1461) and 31.30528862 (Praw = 5.59  10
-05
, 
Pgenome = 0.5771) (Fig. 3a). These SNPs on Chr 31 are located 650 kb upstream and 965 
kb downstream of SOD1, respectively. Evaluation of individual genotypes in this region 
reveals that only four of the 15 cases are homozygous for both SNPs. Five cases are 
homozygous for the associated allele of SNP 31.30528862, while nine cases are 
homozygous for the associated allele of SNP 31.28909487. In the control population, six 
of 69 GSDs are also homozygous for the same allele of SNP 31.28909487. A third 
noteworthy result is on Chr 10 for SNP 10.64801770 (Praw = 6.06  10
-05




GWAS with 100,000 permutations was carried out using 19 cases and 177 control 
dogs. Fourteen SNPs with significant Praw values are located on eight different 
chromosomes (Fig. 3b). Of these, three are within an eight Mb region on Chr 12. Five 
other SNPs within this region are approaching significance (Praw). Further analyses of 
genotypes on Chr 12 reveal a haplotype block extending 4.7 Mb that is present in all 
affected dogs. The strongest associated of these is SNP 12.60274687 (Praw =  1.49  10
-5
, 
Pgenome = 0.3099). Analysis of genotypes for this SNP reveal a common allele that is 
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present in all affected dogs (frequency = 0.83) and is less prevalent among control dogs 
(frequency = 0.46). To further investigate this finding, 35 additional GSDs with ME were 
collected and genotyped for the SNP. Genotype frequencies and odds ratios for SNP 
12.60274687 are shown in Table 1.  
 
 G/G (%) G/A (%) A/A (%) 
ME array   (n=19) 12 (63)
 
  7 (37)   0 (0) 
ME all  (n=54) 33 (61)
a
 20 (37)   1 (2) 
Control      (n=172*) 36 (21) 84 (49) 52 (30) 




, OR=5.937 (95% CI=3.071-11.475) 
Allele (G): P=2.77x10
-10
, OR=4.711 (95% CI=2.817-7.878) 
Table 1. Frequency data for SNP 12.60274687 in GSDs with and without ME. Observed 
genotypes and genotypic frequencies are presented for affected and control dogs. MEarray: 
genotype frequencies of the 19 ME dogs run on Affymetrix SNP arrays; MEall: all ME 
dogs collected.  
 
Pancreatic acinar atrophy 
GWAS with 100,000 permutations was carried out using 100 dogs with PAA and 
79 control dogs (Fig. 3c). Significant Praw values are present for 50 SNPs on 23 
chromosomes (Supplementary Table 1). Chr 12 harbors seven of these SNPs, three of 
which are found in a cluster: 12.3781476, 12.3845215, and 12.4698937. Chr 7 harbors 
six SNPs, four are found in a cluster: 7.11222056, 7.12305239, 7.12310223, and 
7.12424701. On ten of the chromosomes, only one SNP each is strongly linked with 
PAA. On the remaining 11 chromosomes, no two strongly associated SNPs are located 
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within five Mb of each other and no common haplotypes are detected. Six SNPs had 
minor allele frequencies (MAF) < 15%. 
 
 
Figure 3. GWAS using 48,415 SNPs with 100,000 permutations. The genome-wide 
adjusted P values (-log10 P) for each SNP are plotted by chromosome. (a) Fifteen GSDs 
with DM versus 69 healthy control GSDs. (b) Nineteen GSDs with ME versus 177 






Autosomal recessive traits of the dog can be mapped using remarkably small 
numbers of cases [34-35]. In this study, a mere four cases were sufficient to detect a 
strong linkage to Chr 9 and define a two Mb pituitary dwarfism haplotype. While the 
critical interval harbors more than 40 genes, one is an intriguing candidate: LHX3, a LIM 
homeodomain transcription factor vital for pituitary and motor neuron development [36]. 
Genetic variations within LHX3 cause CPHD in humans [37-38]. Mutations in LHX3 in 
humans are associated with a rigid cervical spine, and occasionally mental retardation, 
and deafness [37,39-40]. The GSD pituitary dwarfs do not have clinical signs that 
indicate nervous system involvement [41]. In the mouse, complete loss of LHX3 is lethal 
[42], but mutations within the gene cause a dwarfism phenotype [43,44]44]. 
 Voorbij et al. announced the availability of a genetic test for pituitary dwarfism in 
the GSD [45], but information regarding the gene or mutation has not been published to 
date. Dwarfism in the GSD is rare, so utilization of a definitive genetic test could 
facilitate rapid elimination of the phenotype. Data presented here are surprising because 
the frequency of the two Mb haplotype in control dogs is 4%, suggesting a roughly 8% 
carrier frequency in the general population. Moreover, this estimate is likely low because 
only dogs having the complete two Mb haplotype were considered to be carriers, thereby 






 DM is a devastating disorder of GDSs that has been difficult to eradicate from the 
breed, in part because of a late age of onset and poor diagnostic tools. We identified two 
SNPs on Chr 31 that are strongly associated with the DM phenotype. The SNPs flank 
SOD1, the gene in which Awano et al. identified an E40K missense mutation in DM-
affected dogs from several breeds [14]. Based on genotype frequencies, the authors 
propose that the mutation causes DM in an autosomal recessive fashion with incomplete 
penetrance [14]. In the study reported here, only nine of 15 cases are homozygous for the 
most tightly linked SNP, suggesting that either the relaxed diagnostic criteria used here 
(dogs were not diagnosed postmortem) led to the inclusion of dogs that were 
misdiagnosed, or that heterozygosity for the mutation can produce an affected phenotype. 
Recombination between the SNP and SOD1 exon two mutation (located 652 kb apart) 
may also be a factor (five cases are heterozygous). Six of 69 dogs in the control 
population are homozygous for the SNP, corresponding to approximately 9% 
undiagnosed controls. Similarly, Awano et al. reported that 6% of GSD breed controls 
were homozygous for the SOD1 mutation [14]. The high frequency of clinically normal, 
aged controls that are homozygous for the mutation is consistent with reduced penetrance 
and suggests the involvement of modifier loci and/or environmental factors. In this 
analysis, a second locus is detected on Chr 10 and is supported by six proximal SNPs 
with Praw values approaching significance (< 0.00086). Awano et al. detected weaker 
signals of association on Chrs 6, 18, 20, and 35 [14]. Data herein do not support regions 




 The mode of inheritance of ME has not been previously investigated in the GSD, 
but it has been suggested that the frequent occurrence of affected puppies born to 
clinically normal parents serves as evidence for a recessive mutation. In this work we 
successfully map two simple autosomal recessive traits with 10 and four cases, and a 
complex recessive trait with 15 cases. GWAS using 19 dogs with ME, however, does not 
yield a single, strong region of association. Rather, minor associations are detected on 
eight different chromosomes. It is, therefore, unlikely that ME is inherited in an 
autosomal recessive fashion in the GSD. Similarly, evaluation of inheritance patterns of 
ME in the Miniature Schnauzer did not suggest a simple recessive mode of inheritance 
[17].  
 A locus on Chr 12 is the only one to reach genome-wide significance and have 
supporting proximal SNPs (eight SNPs having Praw values < 0.00014). To verify an 
association, 35 additional ME GSDs were collected and genotyped for the most strongly 
associated SNP in this region. In total, 53 of 54 ME cases are heterozygous or 
homozygous for the associated allele, which occurs at a significantly lower frequency in 
the control population. These data are consistent with an autosomal dominant mode of 
inheritance, with incomplete penetrance and/or modifying loci. On the other hand, it is 
also conceivable that the allele is fully penetrant, but that the control population includes 
dogs with undetected ME. ME varies in severity and can resolve completely after a few 
months, making detection of mild cases difficult. 
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 The dilation and lack of muscle contraction in the esophagus is thought to be a 
neurological defect, rather than a muscular defect [16]. The associated haplotype on Chr 
12 harbors approximately 12 genes, several of which are expressed in the nervous 
system. Additional genome-wide SNP analysis in ME GSDs are necessary to confirm this 
association.  
 
Pancreatic acinar atrophy 
Fifty SNPs, representing 45 loci, exceed genome-wide significance thresholds for 
association with PAA. Many of these map to Chr 12, although only three SNPs on the 
chromosome support the same locus. These SNPs map to the dog leukocyte antigen 
(DLA) complex in the centromeric region of the chromosome. The association of this 
region with PAA is consistent with the autoimmune component of the disease. Previous 
work showed that pancreases from GSDs with PAA show an increased expression of 
DLA-88 [46]. DLA-88 is the most highly polymorphic class I locus of the DLA complex. 
DLA class II loci are associated with several immune-related disorders including: 
diabetes mellitus, anal furunculosis, hypoadrenocorticism, and necrotizing 
meningoencephalitis [47-50]. Canine systemic lupus erythematosus, a classic 
autoimmune disease, is also reported to be associated with alleles of the DLA class II 
loci, and GWAS revealed five additional associated loci [51-52]. The current SNP data, 
together with previous expression data, suggests the DLA region may harbor a genetic 
risk factor for the development of PAA. Further investigation of the DLA loci is planned. 
A second region of interest is located on Chr 7, which has four strongly associated SNPs 
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located within a 1.2 Mb region having 11 genes. None of these genes is known to be 
involved in autoimmune disorders, although several are expressed in acinar cells.  
The data reported here suggest that PAA may be governed by multiple loci with 
small effects, or may be a heterogeneous disorder. Although PAA was thought to be a 
simple autosomal recessive disorder [53-54], the results of a recent test mating between 
two GSDs with PAA indicate more complex genetic underpinnings [28]. The study 
monitored the cTLI scores for the resulting litter of six over the course of the dogs’ lives 
(8-13 years) and the pancreas for each dog was examined at necropsy. Only two of the 
six dogs in the litter were diagnosed with PAA [28]. Similarly, the clinical presentation of 
PAA is inconsistent. The age of onset is variable within families, with diagnoses made in 
puppies and adult dogs alike. The severity of clinical signs also varies, with some dogs 
responding better to traditional treatment regimens than others. To further complicate the 
matter, some GSDs never exhibit clinical signs, despite serum cTLI concentrations that 
are diagnostic for EPI. Variability in age of onset and clinical signs may be indicators of 
genetic heterogeneity. Although PAA is the predominant cause of EPI in dogs, chronic 
pancreatitis, pancreatic cancer, and other underlying medical conditions may also cause 
EPI. 
Variation between processed arrays, a so-called “batch effect,” can cause spurious 
associations [55]. The abundance of isolated SNPs detected in our GWAS for PAA is 
suggestive of such artifacts. However, principal component analysis does not reveal 
subpopulations that indicate a batch effect. Furthermore, no population stratification is 
detected between PAA cases and controls (Supplementary Fig. 1). In addition, we 
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included only the robust “platinum” SNPs in our analysis to minimize artifacts from 
incorrect genotype calls. 
In this study, we used data from a single cohort of GSDs to identify major loci 
associated with pituitary dwarfism, DM, and ME. Our data also reveal that the genetics 
underlying PAA are highly complex. Candidate loci identified herein provide immediate 
targets for future work.  
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CONCLUSIONS, FUTURE DIRECTIONS, AND APPLICATIONS 
 
A COLQ Missense Mutation in Labrador Retrievers Having Congenital Myasthenic 
Syndrome 
 
 In chapter two, a homozygous missense mutation in exon 14 of COLQ 
(c.1010T>C) predicting an amino acid change (I337T) was identified in two Labrador 
Retrievers with endplate acetylcholinesterase (AChE) deficiency (EAD) congenital 
myasthenic syndrome (CMS) through the manual interrogation of SNP array data, and 
the use of microsatellite analysis and sequencing [1]. Analysis of the pedigree as well as 
the absence of this mutation in unaffected, unrelated Labrador Retrievers suggested that 
this mutation recently arose de novo and was transmitted identical by descent through 
shared common ancestors of the two affected puppies [1]. 
 Because we did not have enough affected dogs to utilize the traditional genome-
wide association study (GWAS) approach, we developed a new technique for identifying 
candidate genes in dogs that involves manually interrogating SNP array data for regions 
that fit the simple recessive mode of inheritance pattern expected for EAD CMS [1]. This 
procedure allows for the identification of candidate regions in studies with small sample 
sizes, provided the subjects in question are related. In a similar study by Roach and 
colleagues, the authors investigated a nuclear human family that included both parents 
and their offspring, who both had the same two recessive diseases [2]. By sequencing the 
genomes of these four individuals, compiling SNP haplotypes, and identifying those 
haplotypes that fit a recessive mode of inheritance, these authors were able to identify 





 In the future, manually interrogating SNP array data can be used to identify the 
causative mutations for other recessive diseases and traits, especially those that have been 
observed only in a specific family [1,2]. This method should prove particularly useful in 
canine genetics, where breeding practices in dogs often lead to the appearance of novel 
recessive, and sometimes detrimental, traits. 
 Furthermore, a study in humans was published at the same time as our Labrador 
Retriever study in which the authors identified the same mutation as the one identified in 
the Labrador Retrievers in cases of EAD CMS in a Syrian family [3]. This mutation was 
the same as the one identified in affected Labrador Retrievers at both the nucleotide 
(c.1010T>C) level and the amino acid (I337T) level [1,3]. Not only does this further 
support c.1010T>C (I337T) as a causative mutation in the Labrador Retriever, but it also 
reinforces the dog as a good model system for human CMS cases [1,3]. That is, these 
studies provide examples of the phenotype as well as the genotype being the same in 
humans and dogs for CMS [1,3]. This exact parallel between dog and human disease 
happens rarely; another instance is the identification of the same mutation in cases of 
retinal degeneration diseases in the dog (progressive rod-cone degeneration) and the 
human (retinitis pigmentosa) [4]. Over 200 naturally occurring diseases in dogs have a 
comparable disease in humans [5], and while the mutation underlying the diseases may 
not be the same, the same gene is often implicated, including mutations in SOD1 causing 
amyotrophic lateral sclerosis in humans [6] and degenerative myelopathy in dogs [7]. 
These parallels between dog and human diseases best support the dog as a model for 





A CHRNE Frameshift Mutation Causes Congenital Myasthenic Syndrome in Jack Russell 
Terriers  
 
 In chapter three, I genotyped microsatellite markers flanking the five genes 
encoding the subunits of the acetylcholine receptor (AChR) and evaluated the resulting 
haplotypes for the pattern expected of a simple recessive disease. Through these analyses, 
the candidate genes were narrowed to CHRNB1 and CHRNE, which encode the beta and 
epsilon subunits of the AChR, respectively. Sequencing of the splice sites and coding 
regions of both of these genes revealed an insertion in exon 7 of CHRNE (G193RfsX272) 
that segregates as a simple recessive trait. This mutation was identified using only two 
affected Jack Russell Terrier puppies, their dam, and an unaffected sibling, illustrating 
the utility of pedigree members for the identification of private mutations in simple 
recessive diseases. Future studies of such mutations and potential candidate genes can 
therefore make use of families to identify causative mutations. 
 The results of my two CMS studies [1] and the CHAT mutation identified by 
Proschowsky and colleagues in Old Danish Pointing Dogs [8] suggest that different dog 
breeds exhibit different types of CMS and harbor different causative mutations. Because 
the types of CMS respond differently to the various treatments available, veterinarians 
should be made aware that dogs affected with CMS will need to be treated based on the 
type of CMS that affects their breed (e.g., [1,8]).  Knowing the molecular cause of each 








Genome-wide association studies for multiple diseases of the German Shepherd Dog  
 
 In chapter four, we mapped congenital megaesophagus (ME) in German Shepherd 
Dogs to chromosome (CFA) 12 through the use of a  GWAS evaluating dogs affected 
with congenital ME as cases and dogs affected with three other diseases and healthy dogs 
as controls [9]. As can be observed by comparing Figure 3 from chapter four [9] and the 
new Manhattan plot in Appendix Three (Figure 4), using dogs affected with other 
diseases as controls in our original analysis skewed our original results to include SNPs 
associated with those other diseases. Ideally, more ME-affected German Shepherd Dogs 
should be collected along with healthy, unrelated German Shepherd Dogs and the GWAS 
performed again. This more balanced population, along with the longer LD within the 
breed [10], should result in a more strongly associated region, most likely including at 
least part of the currently associated segment on CFA 12.  If this analysis yields a region 
with more candidate genes than is feasible for sequencing, this chromosomal segment can 
be evaluated in another closely related breed (or breeds) affected by congenital ME. As 
the LD between breeds is shorter, the addition of these closely related breeds to the 
analysis should decrease the size of the associated chromosomal segment, resulting in 
fewer candidate genes. These candidate genes can then be further evaluated, perhaps 
resulting in the identification of the causative mutation(s) and/or a major locus 










Dogs are a good model system for congenital neuromuscular disorders, as 
evidenced in the previous chapters [1,9]. Dogs have clinical signs similar to those of 
humans for many neuromuscular disorders. When developing studies for these 
neuromuscular diseases, there is a potential for larger sample sizes with dogs, as they 
have more offspring per birth compared to humans. In addition, experimental pedigrees 
can be established to study the inheritance and progress of these diseases in dogs [e.g., 
11,12], while this approach is unethical in human studies. Pet dogs also live in the same 
environments as their human owners, which can reduce the environmental differences 
between the human and animal model so that the research can focus on the genetic 
factors. The dog as a model system for neuromuscular diseases is especially evident in 
my study of CMS in Labrador Retrievers, as the exact same mutation was identified in a 
human case of CMS [1,3].  
 To date, three genes have been shown to harbor mutations associated with CMS 
in dog breeds: CHAT in Old Danish Pointing Dogs [8], COLQ in Labrador Retrievers [1], 
and CHRNE in Jack Russell Terriers. In the future, the mutations identified in these three 
papers can be used to screen for carriers in each of these breeds to potentially eliminate 
CMS from these breeds [1,8]. Other breeds with cases of CMS were studied in the 1970s 
and 1980s including Springer Spaniels and Smooth Fox Terriers [13,14]. Because the 
CMS phenotypes are similar to that of CMS in Jack Russell Terriers, it is likely that the 
causative mutations for these CMSs are located in one of the AChR subunit genes [13-





causative mutation; therefore, subsequent screening can be implemented in these breeds 
to ensure that this disease does not become pervasive. In addition, if the causative 
mutation is not found in the genes encoding the AChR subunits, other candidate genes 
are known from human studies [16] that can be evaluated as well. As of this writing, 
there are eighteen genes known to harbor mutations causative for CMS in humans [16]. A 
screen for all eighteen candidate genes would greatly aid in this identification. This 
screen could be developed in one of two ways. First, a set of microsatellite markers 
flanking each of the eighteen genes could be determined and primers encompassing the 
coding regions and splice sites of all eighteen genes could be designed. The genes 
screened in each dog breed could then be selected based on the results of the 
microsatellite analysis as well as the specific clinical signs of the affected dogs (i.e., 
response to anticholinesterase medication). Second, a custom SNP array could be 
designed that included SNPs that are polymorphic across all dog breeds and flanking 
each of the eighteen candidate genes, which could be used in a smaller-scale GWAS 
approach. The first method would be more practical in cases of families with known 
pedigree information. The second method, in turn, would be more practical in cases in 
which the CMS phenotype is seen across the breed and many unrelated dogs are affected. 
In addition, this second method would simultaneously yield data for all eighteen genes, 
while the first would take much longer to yield similar, yet less comprehensive, data.    
 In conclusion, the causative mutations identified in two distinct types of CMS can 
help to identify carriers and cases of CMS [1]. These screens will add to the breeders’ 





lead to the decrease and/or elimination of diseases in these dog breeds. In addition, the 
creation of a screen for all eighteen genes known to harbor CMS mutations [16] can lead 
to the identification of causative CMS mutations in other dog breeds in a more efficient 
manner. Further investigation into the region of interest for congenital ME may one day 
yield candidate genes and causative mutations for this debilitating disease as well. 
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SUPPLEMENTARY MATERIAL FOR CHAPTER TWO 
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Table S1. Primers (5'-3') for amplification of CHRNG, CHRND, and COLQ 
 
Gene Exon(s) 
Forward Primer  
Sequence (5ʹ-3ʹ) 










1 CCTGGCATTTTGTCCATCTT TCAGGGGACAGAGGGTCT ExoSAP 
2 GTTGTCCCACCCGTCACT AAGAAGGGGCTGGCTCTA ExoSAP 
3 GACAGTGGGGGACACAGAG GTGCTAAGGGTGCCGTCC ExoSAP 
4 CCCTCCCTGCCTCTTCTG GGAAAAGGGACAAGTGGACA ExoSAP 
5 GCAGGTGGGGAGTAGCG TCCTTCCCTGCCTCAGTTTC ExoSAP 
6 GGCAGCAGAGGGGAGGAA CCTCCCTGTGCCCACCCT Gel X 
7 GTCAGGCATCCAGTCTCC CACACACGAGACCACCTG Gel X 
8 GGGCATCACACACGAGAC CTACCCTCCTGCCACTCC ExoSAP 
9 CACTACCCTCCTGCCACTC TGTGGCAGGTGTATTATGC ExoSAP 
10 CAACCTTCACCTTCTGCTCT CAGGTTGAGGAGAGAGAAGC ExoSAP 
11 CTTCTTCTCCACTCTATCCCCA TGAGAAGGACCGAAGGAC ExoSAP 







1 TACTGGTCGTGTGTGGTAAGAG CTTCCCCTCCAGCCTCAGTT ExoSAP 
2 TTCCCCTCCAGCCTCAGT CTGGTAGATTGGGATTCTTCATC ExoSAP 
3&4 ATAGGCTCCCTTGGTTGTG CTGAAGCAGGAGGAAGAAG ExoSAP 
5 CCCCTGCTCTGTCCTGTTTAG GGACATACCTACCGACACAAATCT ExoSAP 
6 GGAGACACCCACAAACAGAA CCTCTCCTCACTTCCTCCTG Gel X 
7&8 ACTCACTCTCTCACTTGGTCCTCA CCAGGCACAAATGAGCAGAAG ExoSAP 
9 AATAGGGGAGAGTTGGAAGCA GACCAGAACGATTACAACGAGG ExoSAP 
10 CTGTAAAATAGCCTCCTTGTGTCC GGAGACACACACCCACTTAGATG ExoSAP 









1 GGGAAAGGAGAGAGAGAGACA TTCACCATTCTGCTCTCCG Gel X 
2 CTGGGGGAAGGTTACATCAAG TGTGTCTGTTCTTCCACTGTC Gel X 
3 TCCATTCAAGCCAAGTATGTCTC GCTGCTGCCTAGATGGGTG Gel X 
4&5 AGTCCTGCCTTCCTCACCA GTTGGGGGAGGGATGTGTAT Gel X 
6 TGAACCCCCAAAACAAACC CTTTCTCCTTCGGTTGGACTAC Gel X 
7 TGTCCCTGGTTCATCCTAATCT ATTGAAAGCCCAGTGCCG Gel X 
8 TTACAGCCCCCACTAAAACTTG CAATGGTGAGCAGAAGACA Gel X 
9&10 TGGGCAAGTCCCTAATCTCTG TTGATGAGAGGGTTCCAGCA Gel X 
11 CAGTTGGAAAAAGTCTGGAATGAT GTGTAGGTGGGTGGTGTAGA Gel X 
12 GGCTCCTGCTCCAAAGTG GGAGAGGGCACAGGAGATG Gel X 
13 CGTGGACTTTGACCTTCTTTCT CGCAAAATCAGCCATCCAAC Gel X 
14 CTTCAGGAGGGATGACAGAGTG GAACCTCCTCTTTGAGCC Gel X 
15 AGAAGGTAGCCCCCACAGAC CCTGTCCCTCCCTTTTCCT Gel X 
16 GGCAGTCCCTGGATACAT TTTCTTAGTGCTCCTTATGTTCC Gel X 
17a AGTGGCTGGTGTCTGATG CCAAATAGCCAACCTTCAGT Gel X 
17b GTCCAGTTTCTACCACCTTCATA TGGGTAGGCTTTTGGTGTTC Gel X 
Table S1.  Primers (5'-3') for amplification of CHRNG, CHRND, and COLQ. Primers were 
designed to amplify exons and splice sites. ExoSAP indicates the use of the ExoSAP protocol 






























Table S2. Candidate regions based on allele frequencies. Genomic regions known to harbor 
CMS candidate genes were screened for case allele frequencies of 1.0 and control allele 
frequencies of between 0.14 and 0.50. CHR = chromosome number; SNP = SNP name; BP = 
chromosome position; A1 = allele 1; F_A = frequency of allele 1 in affected dogs (cases); F_U = 






















Table S3. Dogs screened for the COLQ 14 Variant 
  COLQ Exon 14  
Variant Genotype 
Breed Sample Number (n) T/T T/C C/C 
Labrador Retriever (related) 58 40 16 2 
Labrador Retriever (unrelated) 288 288   
Afghan Hound 1 1   
Airedale Terrier 2 2   
Akita 3 3   
American Eskimo Dog 2 2   
Australian Shepherd 2 2   
Basenji 2 2   
Bichon Frise 1 1   
Blue Tick Hound 1 1   
Border Collie 2 2   
Boston Terrier 2 2   
Boxer 2 2   
Briard 2 2   
Bull Terrier 1 1   
Cairn Terrier 2 2   
Cardigan Welsh Corgi 2 2   
Catahoula Leopard Dog 2 2   
Cavalier King Charles Spaniel 2 2   
Chihuahua 2 2   
Chinese Shar-Pei 1 1   
Chow Chow 1 1   
Cocker Spaniel 2 2   
Collie 3 3   
Dachshund 2 2   
Doberman Pinscher 1 1   
English Bulldog 2 2   
English Setter 2 2   
English Springer Spaniel 2 2   
Flat-Coated Retriever 1 1   
German Shepherd Dog 2 2   
Golden Retriever 3 3   
Great Dane 2 2   
Havanese 1 1   
Irish Setter 2 2   
Lhasa Apso 1 1   
Maltese 1 1   
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Miniature Poodle 2 2   
Miniature Schnauzer 2 2   
New Guinea Singing Dog 2 2   
Newfoundland 2 2   
Norwegian Elkhound 2 2   
Papillon 1 1   
Pekingese 1 1   
Pembroke Welsh Corgi 2 2   
Petit Basset Griffon Vendéen 2 2   
Podengo 1 1   
Polish Lowland Sheepdog 1 1   
Portuguese Water Dog 1 1   
Pyrenean Shepherd 2 2   
Rhodesian Ridgeback 2 2   
Rottweiler 1 1   
Saint Bernard 2 2   
Shetland Sheepdog 2 2   
Shih Tzu 1 1   
Shiloh Shepherd 1 1   
Siberian Husky 2 2   
Silken Windhound 2 2   
Silky Terrier 1 1   
Swedish Vallhund 2 2   
Tibetan Terrier 2 2   
Vizsla 1 1   
Weimaraner 2 2   
Welsh Fox Terrier 2 2   
West Highland White Terrier 2 2   
Wire Fox Terrier 2 2   
Yorkshire Terrier 2 2   
Table S3. Dogs screened for the COLQ 14 variant. Digestion with Bts1 was used to genotype the 
2 affected dogs, 56 other members of the Labrador Retriever pedigree, 288 unrelated Labrador 









Rinz CJ, Levine J, Minor KM, Humphries HD, Lara R, et al. (2014) A COLQ Missense Mutation 
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Supplementary Figure 1. Principal component analysis of 98 GSDs with PAA versus 79 healthy control 
GSDs. The x-axis is principal component 1 and the y-axis is principal component 2. Both populations 

















SNP Praw EMP2 FDR_BH 
chr35.4925078 1.59E-11 2.00E-05 6.43E-07 
chr12.58146406 9.28E-11 2.00E-05 1.30E-06 
chr28.32676786 9.59E-11 2.00E-05 1.30E-06 
chr12.23177472 1.48E-10 2.00E-05 1.50E-06 
chr33.30105637 1.85E-10 2.00E-05 1.50E-06 
chr15.40294695 3.03E-10 2.00E-05 2.05E-06 
chr7.82831339 2.43E-09 0.00026 1.40E-05 
chr5.51353689 3.44E-09 0.00035 1.73E-05 
chr3.76398656 3.85E-09 0.00039 1.73E-05 
chr33.25987767 5.02E-09 0.00043 2.03E-05 
chr1.9328042 1.18E-08 0.00083 4.36E-05 
chr24.31358922 1.77E-08 0.00115 5.97E-05 
chr37.12660891 3.69E-08 0.00225 0.0001149 
chr9.10239350 4.07E-08 0.00244 0.0001177 
chr6.39598998 2.80E-07 0.01431 0.0007564 
chr13.30418286 3.16E-07 0.01574 0.0007722 
chr10.13435580 3.24E-07 0.01598 0.0007722 
chr35.19780099 3.67E-07 0.01791 0.0008268 
chr28.13143663 4.73E-07 0.02195 0.001009 
chr4.13107661 7.54E-07 0.03298 0.001527 
chr4.4080795 8.72E-07 0.03707 0.001675 
chr14.54484895 9.10E-07 0.03814 0.001675 
chr23.14905565 9.67E-07 0.04017 0.001703 
chr17.44088133 1.47E-06 0.05733 0.002474 
chr5.68085129 1.94E-06 0.0711 0.003082 
chr2.86073514 1.98E-06 0.07227 0.003082 
chr12.12567352 4.83E-06 0.1536 0.007242 
chr10.68614890 5.75E-06 0.1737 0.008223 
chr3.93468384 5.89E-06 0.1771 0.008223 
chr12.27205596 6.76E-06 0.1981 0.009124 
chr12.3781476 8.88E-06 0.2478 0.01161 
chr7.12305239 1.16E-05 0.2998 0.01469 
chr28.38709005 1.41E-05 0.3461 0.01731 
chr26.20243802 1.49E-05 0.3599 0.01778 
chr12.4698937 1.73E-05 0.3985 0.01999 
chr9.54243104 1.86E-05 0.4241 0.02098 
chr7.5792722 2.79E-05 0.5349 0.03059 
chr2.18072233 3.26E-05 0.5823 0.03474 
chr3.29459535 3.47E-05 0.6062 0.03574 
chr7.11222056 3.53E-05 0.6125 0.03574 
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chr6.33280800 4.06E-05 0.655 0.04011 
chr12.3845215 4.72E-05 0.7004 0.04552 
chr7.12424701 4.92E-05 0.7151 0.046 
chrX.87975142 5.00E-05 0.7203 0.046 
chr6.18214638 5.42E-05 0.7426 0.04881 
chr17.5088861 6.64E-05 0.8006 0.0582 
chr7.12310223 6.75E-05 0.808 0.0582 
chr31.36637612 8.75E-05 0.8689 0.07383 
chr17.52274900 9.12E-05 0.8774 0.07542 
chr5.3236960 9.98E-05 0.898 0.08084 
Supplementary Table 1: Uncorrected and corrected P values (PAA) are shown for the 50 SNPs 
with significant Praw values (P<0.0001). Corrected P values are from 100,000 permutations 



























































ADDENDUM TO CHAPTER FOUR 























Addendum to Chapter Four 
(Genome-wide association studies for multiple diseases of the German Shepherd Dog) 
 
 Since Tsai, et al.’s “Genome-wide association studies for multiple diseases of the German 
Shepherd Dog” was published in 2012 [1], we have performed the GWAS analysis using 
different poulation parameters for the congenital megaesophagus (ME) affected German 
Shepherd Dogs (GSDs). For this analysis, we used the 19 affected GSDs and only those controls 
(67 dogs) that were healthy (i.e., were not diagnosed with any of the other diseases) from the 
original paper. This analysis yielded a significant association on CFA12 (Figure 4). 
 
 
Figure 4. GWAS using 48,415 SNPs with 100,000 permutations. Nineteen cases (GSDs affected 
with congenital ME) and 67 healthy controls (healthy GSDs) were run through PLINK. The  
-log10(P) for every SNP was plotted by chromosome and a significant association identified on 
CFA12.  
 
 In our previous study, SNP 12.60274687 was most strongly associated with congenital 
ME (Praw =  1.49x10
-5
 Tsai, et al. 2012). In our new analysis, the same SNP was again most 
strongly associated, with Praw = 4.01x10
-6
. Therefore, I genotyped a total of 74 affected GSDs 
(including the 35 genotyped for Tsai, et al. 2012) as well as 63 dogs from an additional 33 breeds 
for the 12.60274687 SNP (Table 2). As discussed in Tsai, et al. 2012 [1], the G allele of 
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12.60274687 is most likely associated with ME in GSDs as approximately 96% of affected dogs 
in that study were either homozygous G or heterozygous. However, this G allele it is not likely 
associated with ME in the other breeds as many affected dogs were homozygous A (see Table 2). 
 In addition, many of the dogs harbored an indel associated with the G allele (Table 2) that 
involves the deletion of 5’-CTAACT-3’ at position 12.60274679-12.60274684 and an insertion 
of 5’-GATAGACTC-3’ beginning at position 12.60274679 (positions based on canFam2). This 
indel was only observed with the G allele and was not present in sequences with the A allele. As 
this indel was not present with every G allele in every affected dog, it is uncertain whether it 
plays a role in ME. 
 12.60274687 Genotypes 
Breed (n) G/G G/A A/A 
American Bulldog (1)  1  
Australian Shepherd (1)  1  
Boston Terrier (1)  1  
Boxer (1)  1*  
Chihuahua (1)   1 
Dachshund (5)  4* 1 
English Bulldog (1)  1*  
French Bulldog (1) 1   
German Shepherd Dog (74) 43 28 3 
Golden Doodle (1)   1 
Great Dane (10) 4 5 1 
Irish Setter (1)   1 
Jack Russell Terrier (1) 1   
Labrador Retriever (1)  1*  
Lhasa Apso (3) 2* 1*  
Miniature Schnauzer (4) 3* 1*  
Mixed Breed (6) 5 1  
Newfoundland (2)  2  
Papillon (1)   1 
Pembroke Welsh Corgi (1)   1 
Portuguese Water Dog (1)   1 
Rat Terrier (1)   1 
Rhodesian Ridgeback (1)   1 
Saint Bernard (1) 1   
Shiloh Shepherd (1)  1  
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Silken Windhound (3) 2 1  
Soft Coated Wheaten Terrier (1) 1   
Standard Poodle (2) 1*  1 
Vizla (1)   1 
Weimaraner (4)   4 
Welsh Terrier (2)  1 1 
Wire-Haired Fox Terrier (1)  1  
Yorshire Terrier (1)  1  
Table 2. All dogs screened for 12.60274687 SNP. Sanger sequencing was used to genotype a 
total of 137 affected (congenital ME) dogs representing 33 breeds for the 12.60274687 SNP. 
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